BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113:5711-5719. [PMID: 19299333 DOI: 10.1182/blood-2008-10-143560] [Cited by in Crossref: 367] [Cited by in F6Publishing: 330] [Article Influence: 28.2] [Reference Citation Analysis]
Number Citing Articles
1 Razonable R. Direct and indirect effects of cytomegalovirus: can we prevent them? Enferm Infecc Microbiol Clin. 2010;28:1-5. [PMID: 20022410 DOI: 10.1016/j.eimc.2009.07.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
2 Camacho-bydume C, Mauguen A, Rodriguez-sanchez MI, Klein E, Kernan NA, Prockop S, Boelens JJ, Papanicolaou GA, Cancio M. Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients. Cytotherapy 2022. [DOI: 10.1016/j.jcyt.2021.10.002] [Reference Citation Analysis]
3 George B, Kerridge I, Gilroy N, Huang G, Hertzberg M, Bradstock K, Gottlieb D. A risk score for early cytomegalovirus reactivation after allogeneic stem cell transplantation identifies low-, intermediate-, and high-risk groups: reactivation risk is increased by graft-versus-host disease only in the intermediate-risk group. Transpl Infect Dis 2012;14:141-8. [DOI: 10.1111/j.1399-3062.2011.00706.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
4 Mariotti J, Maura F, Spina F, Roncari L, Dodero A, Farina L, Montefusco V, Carniti C, Sarina B, Patriarca F, Rambaldi A, Onida F, Olivieri A, Zallio F, Corradini P. Impact of Cytomegalovirus Replication and Cytomegalovirus Serostatus on the Outcome of Patients with B Cell Lymphoma after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2014;20:885-90. [DOI: 10.1016/j.bbmt.2014.02.015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
5 Frenzel K, Ganepola S, Michel D, Thiel E, Krüger DH, Uharek L, Hofmann J. Antiviral function and efficacy of polyvalent immunoglobulin products against CMV isolates in different human cell lines. Med Microbiol Immunol 2012;201:277-86. [DOI: 10.1007/s00430-012-0229-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
6 Daenthanasanmak A, Salguero G, Sundarasetty BS, Waskow C, Cosgun KN, Guzman CA, Riese P, Gerasch L, Schneider A, Ingendoh A, Messerle M, Gabaev I, Woelk B, Ruggiero E, Schmidt M, von Kalle C, Figueiredo C, Eiz-Vesper B, von Kaisenberg C, Ganser A, Stripecke R. Engineered dendritic cells from cord blood and adult blood accelerate effector T cell immune reconstitution against HCMV. Mol Ther Methods Clin Dev 2015;1:14060. [PMID: 26052526 DOI: 10.1038/mtm.2014.60] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
7 Chan ST, Logan AC. The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters. Blood Reviews 2017;31:173-83. [DOI: 10.1016/j.blre.2017.01.002] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
8 Wang XC, Pang H, Xu X, Schmitt A, Freund M, Schmitt M, Chen BA. Streptamer versus tetramer-based selection of functional cytomegalovirus-specific T cells. J Formos Med Assoc 2013;112:338-45. [PMID: 23787011 DOI: 10.1016/j.jfma.2012.02.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
9 Zhao XY, Pei XY, Chang YJ, Yu XX, Xu LP, Wang Y, Zhang XH, Liu KY, Huang XJ. First-line Therapy With Donor-derived Human Cytomegalovirus (HCMV)-specific T Cells Reduces Persistent HCMV Infection by Promoting Antiviral Immunity After Allogenic Stem Cell Transplantation. Clin Infect Dis. 2020;70:1429-1437. [PMID: 31067570 DOI: 10.1093/cid/ciz368] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
10 Ross SA, Novak Z, Pati S, Boppana SB. Overview of the diagnosis of cytomegalovirus infection. Infect Disord Drug Targets 2011;11:466-74. [PMID: 21827433 DOI: 10.2174/187152611797636703] [Cited by in Crossref: 105] [Cited by in F6Publishing: 83] [Article Influence: 10.5] [Reference Citation Analysis]
11 Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Infect Dis Clin North Am 2010;24:257-72. [PMID: 20466269 DOI: 10.1016/j.idc.2010.01.010] [Cited by in Crossref: 98] [Cited by in F6Publishing: 81] [Article Influence: 8.2] [Reference Citation Analysis]
12 Khansarinejad B, Soleimanjahi H, Mirab Samiee S, Hamidieh AA, Paryan M, Sanahmadi Y. Quantitation of human cytomegalovirus DNA in plasma using an affordable in-house qPCR assay. Journal of Virological Methods 2012;183:170-5. [DOI: 10.1016/j.jviromet.2012.04.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
13 Marchesi F, Pimpinelli F, Ensoli F, Mengarelli A. Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant. Hematological Oncology 2018;36:381-91. [DOI: 10.1002/hon.2453] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
14 Yong MK, Shigle TL, Kim YJ, Carpenter PA, Chemaly RF, Papanicolaou GA. American Society for Transplantation and Cellular Therapy Series: #4 - Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation. Transplant Cell Ther 2021:S2666-6367(21)01252-5. [PMID: 34560310 DOI: 10.1016/j.jtct.2021.09.010] [Reference Citation Analysis]
15 El Haddad L, Ghantoji SS, Park AK, Batista MV, Schelfhout J, Hachem J, Lobo Y, Jiang Y, Rondon G, Champlin R, Chemaly RF. Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients. J Med Virol 2020;92:86-95. [PMID: 31448830 DOI: 10.1002/jmv.25574] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
16 Derigs P, Radujkovic A, Schubert ML, Schnitzler P, Schöning T, Müller-Tidow C, Hegenbart U, Schönland SO, Luft T, Dreger P, Schmitt M. Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data. Ann Hematol 2021;100:2087-93. [PMID: 33270162 DOI: 10.1007/s00277-020-04362-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Stern L, Withers B, Avdic S, Gottlieb D, Abendroth A, Blyth E, Slobedman B. Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Front Microbiol 2019;10:1186. [PMID: 31191499 DOI: 10.3389/fmicb.2019.01186] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 15.0] [Reference Citation Analysis]
18 Costa-García M, Ataya M, Moraru M, Vilches C, López-Botet M, Muntasell A. Human Cytomegalovirus Antigen Presentation by HLA-DR+ NKG2C+ Adaptive NK Cells Specifically Activates Polyfunctional Effector Memory CD4+ T Lymphocytes. Front Immunol 2019;10:687. [PMID: 31001281 DOI: 10.3389/fimmu.2019.00687] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
19 Dong MY, Tang BL, Zhu XY, Cheng SQ, Fang XC, Tong J, Wan X, Zheng CC, Liu HL, Sun ZM. Protective Effects of Cytomegalovirus DNA Copies ≧1000/mL for AML Patients in Complete Remission After Single Cord Blood Transplantation. Infect Drug Resist 2020;13:373-83. [PMID: 32104009 DOI: 10.2147/IDR.S225465] [Reference Citation Analysis]
20 Król L, Stuchlý J, Hubáček P, Keslová P, Sedláček P, Starý J, Hrušák O, Kalina T. Signature profiles of CMV-specific T-cells in patients with CMV reactivation after hematopoietic SCT. Bone Marrow Transplant 2011;46:1089-98. [PMID: 21057553 DOI: 10.1038/bmt.2010.261] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
21 Pillet S, Roblin X, Cornillon J, Mariat C, Pozzetto B. Quantification of cytomegalovirus viral load. Expert Rev Anti Infect Ther. 2014;12:193-210. [PMID: 24341395 DOI: 10.1586/14787210.2014.870887] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
22 Mori Y, Jinnouchi F, Takenaka K, Aoki T, Kuriyama T, Kadowaki M, Odawara J, Ueno T, Kohno K, Harada T, Yoshimoto G, Takase K, Henzan H, Kato K, Ito Y, Kamimura T, Ohno Y, Ogawa R, Eto T, Nagafuji K, Akashi K, Miyamoto T. Efficacy of prophylactic letermovir for cytomegalovirus reactivation in hematopoietic cell transplantation: a multicenter real-world data. Bone Marrow Transplant 2021;56:853-62. [DOI: 10.1038/s41409-020-01082-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
23 Solano C, Navarro D. How to best manage cytomegalovirus infection in the allogeneic stem cell transplant setting: future prospects. Future Virology 2016;11:603-6. [DOI: 10.2217/fvl-2016-0086] [Reference Citation Analysis]
24 Zhou YP, Jin J, Ding Y, Chee YL, Koh LP, Chng WJ, Chan DS, Hsu LY. Direct costs associated with febrile neutropenia in inpatients with hematological diseases in Singapore. Support Care Cancer 2014;22:1447-51. [DOI: 10.1007/s00520-013-2055-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
25 Cantoni N, Hirsch HH, Khanna N, Gerull S, Buser A, Bucher C, Halter J, Heim D, Tichelli A, Gratwohl A, Stern M. Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease. Biol Blood Marrow Transplant 2010;16:1309-14. [PMID: 20353832 DOI: 10.1016/j.bbmt.2010.03.020] [Cited by in Crossref: 128] [Cited by in F6Publishing: 124] [Article Influence: 10.7] [Reference Citation Analysis]
26 Beauvais D, Drumez E, Blaise D, Peffault de Latour R, Forcade E, Ceballos P, Uyttebroeck A, Labussière H, Nguyen S, Bourhis JH, Chevallier P, Thiebaut A, Poiré X, Maury S, Deconinck E, Cluzeau T, Brissot E, Huynh A, Rubio MT, Duhamel A, Yakoub-Agha I. Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study. Bone Marrow Transplant 2021;56:1305-15. [PMID: 33339900 DOI: 10.1038/s41409-020-01178-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Shmueli E, Or R, Shapira MY, Resnick IB, Caplan O, Bdolah-Abram T, Wolf DG. High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation. J Infect Dis 2014;209:557-61. [PMID: 23983215 DOI: 10.1093/infdis/jit475] [Cited by in Crossref: 70] [Cited by in F6Publishing: 55] [Article Influence: 7.8] [Reference Citation Analysis]
28 Phasuk N, Keatkla J, Rattanasiri S, Techasaensiri C, Anurathapan U, Apiwattanakul N. Monitoring of cytomegalovirus infection in non-transplant pediatric acute lymphoblastic leukemia patients during chemotherapy. Medicine (Baltimore) 2019;98:e14256. [PMID: 30681620 DOI: 10.1097/MD.0000000000014256] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
29 Griffiths P. The direct and indirect consequences of cytomegalovirus infection and potential benefits of vaccination. Antiviral Res 2020;176:104732. [PMID: 32081353 DOI: 10.1016/j.antiviral.2020.104732] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
30 Pandey RK, Ojha R, Dipti K, Kumar R, Prajapati VK. Immunoselective algorithm to devise multi-epitope subunit vaccine fighting against human cytomegalovirus infection. Infection, Genetics and Evolution 2020;82:104282. [DOI: 10.1016/j.meegid.2020.104282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Huang YT, Su Y, Kim SJ, Nichols P, Burack D, Maloy M, Giralt S, Perales MA, Jakubowski AA, Papanicolaou GA. Cytomegalovirus Infection in Allogeneic Hematopoietic Cell Transplantation Managed by the Preemptive Approach: Estimating the Impact on Healthcare Resource Utilization and Outcomes. Biol Blood Marrow Transplant 2019;25:791-9. [PMID: 30476551 DOI: 10.1016/j.bbmt.2018.11.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
32 Hantz S, Garnier-Geoffroy F, Mazeron MC, Garrigue I, Merville P, Mengelle C, Rostaing L, Saint Marcoux F, Essig M, Rerolle JP. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother. 2010;65:2628-2640. [PMID: 20961907 DOI: 10.1093/jac/dkq368] [Cited by in Crossref: 110] [Cited by in F6Publishing: 82] [Article Influence: 9.2] [Reference Citation Analysis]
33 Camargo JF, Kimble E, Rosa R, Shimose LA, Bueno MX, Jeyakumar N, Morris MI, Abbo LM, Simkins J, Alencar MC, Benjamin C, Wieder E, Jimenez A, Beitinjaneh A, Goodman M, Byrnes JJ, Lekakis LJ, Pereira D, Komanduri KV. Impact of Cytomegalovirus Viral Load on Probability of Spontaneous Clearance and Response to Preemptive Therapy in Allogeneic Stem Cell Transplantation Recipients. Biol Blood Marrow Transplant 2018;24:806-14. [PMID: 29217388 DOI: 10.1016/j.bbmt.2017.11.038] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
34 Green ML. Viral Pneumonia in Patients with Hematopoietic Cell Transplantation and Hematologic Malignancies. Clin Chest Med 2017;38:295-305. [PMID: 28477640 DOI: 10.1016/j.ccm.2016.12.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
35 Choi YJ, Kim SB, Kim JH, Park SH, Park MS, Kim JM, Han SH, Shin EC. Impaired polyfunctionality of CD8+ T cells in severe sepsis patients with human cytomegalovirus reactivation. Exp Mol Med 2017;49:e382. [PMID: 28960213 DOI: 10.1038/emm.2017.146] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
36 Ogonek J, Kralj Juric M, Ghimire S, Varanasi PR, Holler E, Greinix H, Weissinger E. Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol. 2016;7:507. [PMID: 27909435 DOI: 10.3389/fimmu.2016.00507] [Cited by in Crossref: 131] [Cited by in F6Publishing: 132] [Article Influence: 21.8] [Reference Citation Analysis]
37 Yi ES, Lee JW, Kim YJ, Sung KW, Koo HH, Yoo KH. Risk factors and outcomes of cytomegalovirus infection in children post cord blood transplantation with focus on impact of graft-versus-host disease and immunosuppressants. Ann Hematol 2021. [PMID: 34725714 DOI: 10.1007/s00277-021-04707-5] [Reference Citation Analysis]
38 Limaye AP, Babu TM, Boeckh M. Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation. Clin Microbiol Rev 2020;34:e00043-19. [PMID: 33115722 DOI: 10.1128/CMR.00043-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
39 Travi G, Pergam SA. Cytomegalovirus pneumonia in hematopoietic stem cell recipients. J Intensive Care Med 2014;29:200-12. [PMID: 23753231 DOI: 10.1177/0885066613476454] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
40 Dhingra A, Götting J, Varanasi PR, Steinbrueck L, Camiolo S, Zischke J, Heim A, Schulz TF, Weissinger EM, Kay-Fedorov PC, Davison AJ, Suárez NM, Ganzenmueller T. Human cytomegalovirus multiple-strain infections and viral population diversity in haematopoietic stem cell transplant recipients analysed by high-throughput sequencing. Med Microbiol Immunol 2021;210:291-304. [PMID: 34611744 DOI: 10.1007/s00430-021-00722-5] [Reference Citation Analysis]
41 Tzannou I, Leen AM. Accelerating immune reconstitution after hematopoietic stem cell transplantation. Clin Transl Immunology 2014;3:e11. [PMID: 25505959 DOI: 10.1038/cti.2014.2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
42 Eiz-Vesper B, Maecker-Kolhoff B, Blasczyk R. Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry. Front Immunol 2012;3:410. [PMID: 23372567 DOI: 10.3389/fimmu.2012.00410] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
43 Zöllner SK, Herbrüggen H, Kolve H, Mihailovic N, Schubert F, Reicherts C, Rössig C, Groll AH. Cytomegalovirus retinitis in children and adolescents with acute leukemia following allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2019;21:e13089. [PMID: 30972869 DOI: 10.1111/tid.13089] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
44 Takenaka K, Nishida T, Asano-Mori Y, Oshima K, Ohashi K, Mori T, Kanamori H, Miyamura K, Kato C, Kobayashi N, Uchida N, Nakamae H, Ichinohe T, Morishima Y, Suzuki R, Yamaguchi T, Fukuda T. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Biol Blood Marrow Transplant 2015;21:2008-16. [PMID: 26211985 DOI: 10.1016/j.bbmt.2015.07.019] [Cited by in Crossref: 85] [Cited by in F6Publishing: 87] [Article Influence: 12.1] [Reference Citation Analysis]
45 Suárez-Lledó M, Marcos MÁ, Cuatrecasas M, Bombi JA, Fernández-Avilés F, Magnano L, Martínez-Cibrián N, Llobet N, Rosiñol L, Gutiérrez-García G, Jorge S, Martínez C, Rovira M, Urbano-Ispizua Á. Quantitative PCR Is Faster, More Objective, and More Reliable Than Immunohistochemistry for the Diagnosis of Cytomegalovirus Gastrointestinal Disease in Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 2019;25:2281-6. [PMID: 31325586 DOI: 10.1016/j.bbmt.2019.07.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
46 Kalra A, Williamson T, Daly A, Savoie ML, Stewart DA, Khan F, Storek J. Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin-Conditioned Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2016;22:1654-63. [PMID: 27246372 DOI: 10.1016/j.bbmt.2016.05.020] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
47 Proff J, Brey CU, Ensser A, Holter W, Lehner M. Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2-CH3 IgG spacer domains. J Transl Med 2018;16:26. [PMID: 29422056 DOI: 10.1186/s12967-018-1394-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
48 Chen XF, Li TR, Yang H, Shao Y, Zhang J, Zhang W, Yu B, Wei Z, Wu B, Yu L. Detection of Two Drug-Resistance Mutants of the Cytomegalovirus by High-Resolution Melting Analysis. J Clin Lab Anal 2016;30:319-25. [PMID: 25968338 DOI: 10.1002/jcla.21858] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Marr KA. Delayed opportunistic infections in hematopoietic stem cell transplantation patients: a surmountable challenge. Hematology 2012;2012:265-70. [DOI: 10.1182/asheducation.v2012.1.265.3800160] [Cited by in Crossref: 31] [Article Influence: 3.1] [Reference Citation Analysis]
50 Yong MK, Lewin SR, Manuel O. Immune Monitoring for CMV in Transplantation. Curr Infect Dis Rep 2018;20:4. [PMID: 29542023 DOI: 10.1007/s11908-018-0610-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
51 Yokose T, Obara H, Shinoda M, Nakano Y, Kitago M, Yagi H, Abe Y, Yamada Y, Matsubara K, Oshima G, Hori S, Ibuki S, Higashi H, Masuda Y, Hayashi M, Mori T, Kawaida M, Fujimura T, Hoshino K, Kameyama K, Kuroda T, Kitagawa Y. Colon perforation due to antigenemia-negative cytomegalovirus gastroenteritis after liver transplantation: A case report and review of literature. World J Gastroenterol 2019; 25(15): 1899-1906 [PMID: 31057303 DOI: 10.3748/wjg.v25.i15.1899] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Fang J, Su Y, Zavras PD, Raval AD, Tang Y, Perales MA, Giralt S, Stern A, Papanicolaou GA. Impact of Preemptive Therapy for Cytomegalovirus on Hospitalizations and Cost after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2020;26:1937-47. [PMID: 32640313 DOI: 10.1016/j.bbmt.2020.06.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Kronig I, Elkrief L, Berney T, Van Delden C, Neofytos D. Combination Treatment With Letermovir and Ganciclovir for Maintenance Therapy of Multidrug-resistant CMV Infection in a Liver Transplant Recipient. Transplantation 2020;104:e248-9. [DOI: 10.1097/tp.0000000000003260] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
54 Ljungman P, Schmitt M, Marty FM, Maertens J, Chemaly RF, Kartsonis NA, Butterton JR, Wan H, Teal VL, Sarratt K, Murata Y, Leavitt RY, Badshah C. A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation. Clin Infect Dis 2020;70:1525-33. [PMID: 31179485 DOI: 10.1093/cid/ciz490] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 41.0] [Reference Citation Analysis]
55 Griffiths PD, Mahungu T. Why CMV is a candidate for elimination and then eradication. Journal of Virus Eradication 2016;2:131-5. [DOI: 10.1016/s2055-6640(20)30455-6] [Cited by in Crossref: 6] [Article Influence: 1.0] [Reference Citation Analysis]
56 Ganzenmueller T, Henke-Gendo C, Schlué J, Wedemeyer J, Huebner S, Heim A. Quantification of cytomegalovirus DNA levels in intestinal biopsies as a diagnostic tool for CMV intestinal disease. J Clin Virol. 2009;46:254-258. [PMID: 19748823 DOI: 10.1016/j.jcv.2009.08.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
57 Lin CT, Hsueh PR, Wu SJ, Yao M, Ko BS, Li CC, Hsu CA, Tang JL, Tien HF. Repurposing Nilotinib for Cytomegalovirus Infection Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Arm, Phase II Trial. Biol Blood Marrow Transplant 2018;24:2310-5. [PMID: 30026110 DOI: 10.1016/j.bbmt.2018.07.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
58 Hirsch HH, Lautenschlager I, Pinsky BA, Cardeñoso L, Aslam S, Cobb B, Vilchez RA, Valsamakis A. An international multicenter performance analysis of cytomegalovirus load tests. Clin Infect Dis 2013;56:367-73. [PMID: 23097587 DOI: 10.1093/cid/cis900] [Cited by in Crossref: 102] [Cited by in F6Publishing: 79] [Article Influence: 10.2] [Reference Citation Analysis]
59 Sung AD, Giri VK, Tang H, Nichols KR, Lew MV, Bohannon L, Ren Y, Jung S, Dalton T, Bush A, Van Opstal J, Artica A, Messina J, Shelby R, Frith J, Lassiter M, Burleson J, Leonard K, Potter AS, Choi T, Gasparetto CJ, Horwitz ME, Long GD, Lopez RD, Sarantopoulos S, Chao NJ. Home-Based Hematopoietic Cell Transplantation in the United States. Transplantation and Cellular Therapy 2022. [DOI: 10.1016/j.jtct.2022.01.015] [Reference Citation Analysis]
60 Bao X, Zhu Q, Xue S, Xu Y, Ma X, Chen F, Hu X, Zhu Z, Chen S, Sun A, Wu D, Song Y, Qiu H. Risk factors of clinically refractory CMV reactivation following allogeneic HSCT: a single-center study in China. Bone Marrow Transplant 2016;51:1625-7. [DOI: 10.1038/bmt.2016.231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
61 López-Botet M, Vilches C, Redondo-Pachón D, Muntasell A, Pupuleku A, Yélamos J, Pascual J, Crespo M. Dual Role of Natural Killer Cells on Graft Rejection and Control of Cytomegalovirus Infection in Renal Transplantation. Front Immunol 2017;8:166. [PMID: 28261220 DOI: 10.3389/fimmu.2017.00166] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
62 Carnevale-schianca F, Caravelli D, Gallo S, Coha V, D'ambrosio L, Vassallo E, Fizzotti M, Nesi F, Gioeni L, Berger M, Polo A, Gammaitoni L, Becco P, Giraudo L, Mangioni M, Sangiolo D, Grignani G, Rota–scalabrini D, Sottile A, Fagioli F, Aglietta M. Post-Transplant Cyclophosphamide and Tacrolimus–Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. Biology of Blood and Marrow Transplantation 2017;23:459-66. [DOI: 10.1016/j.bbmt.2016.12.636] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
63 Hayden RT, Gu Z, Ingersoll J, Abdul-Ali D, Shi L, Pounds S, Caliendo AM. Comparison of droplet digital PCR to real-time PCR for quantitative detection of cytomegalovirus. J Clin Microbiol. 2013;51:540-546. [PMID: 23224089 DOI: 10.1128/jcm.02620-12] [Cited by in Crossref: 223] [Cited by in F6Publishing: 91] [Article Influence: 22.3] [Reference Citation Analysis]
64 Sundarasetty BS, Kloess S, Oberschmidt O, Naundorf S, Kuehlcke K, Daenthanasanmak A, Gerasch L, Figueiredo C, Blasczyk R, Ruggiero E, Fronza R, Schmidt M, von Kalle C, Rothe M, Ganser A, Koehl U, Stripecke R. Generation of lentivirus-induced dendritic cells under GMP-compliant conditions for adaptive immune reconstitution against cytomegalovirus after stem cell transplantation. J Transl Med 2015;13:240. [PMID: 26198406 DOI: 10.1186/s12967-015-0599-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
65 Cho BS, Yahng SA, Kim JH, Yoon JH, Shin SH, Lee SE, Choi SM, Lee DG, Eom KS, Park G, Kim YJ, Kim HJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS, Park CW. Impact of cytomegalovirus gastrointestinal disease on the clinical outcomes in patients with gastrointestinal graft-versus-host disease in the era of preemptive therapy. Ann Hematol 2013;92:497-504. [PMID: 23180439 DOI: 10.1007/s00277-012-1632-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
66 Yue C, Kang Z, Ai K, Xu D, Wu J, Pan Y, Yan J, Liu M, Liu Q. Virus infection facilitates the development of severe pneumonia in transplant patients with hematologic malignancies. Oncotarget 2016;7:53930-40. [PMID: 27340772 DOI: 10.18632/oncotarget.10182] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
67 Ljungman P, Bermudez A, Logan AC, Kharfan-Dabaja MA, Chevallier P, Martino R, Wulf G, Selleslag D, Kakihana K, Langston A, Lee DG, Solano C, Okamoto S, Smith LR, Boeckh M, Wingard JR, Cywin B, Fredericks C, Lademacher C, Wang X, Young J, Maertens J. A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. EClinicalMedicine 2021;33:100787. [PMID: 33842870 DOI: 10.1016/j.eclinm.2021.100787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
68 Lin A, Maloy M, Su Y, Bhatt V, Derespiris L, Griffin M, Lau C, Proli A, Barker J, Shaffer B, Giralt SA, Jakubowski AA, Papadopoulos EB, Papanicolaou GA, Seo SK, Perales M. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real‐world experience. Transpl Infect Dis 2019;21. [DOI: 10.1111/tid.13187] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
69 Alain S, Lachaise V, Hantz S, Denis F. [Comparison between the LightCycler CMV Quant Kit (Roche Diagnostics) with a standardized in-house Taqman assay for cytomegalovirus blood viral load quantification]. Pathol Biol (Paris) 2010;58:156-61. [PMID: 19875243 DOI: 10.1016/j.patbio.2009.08.003] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
70 Flinsenberg TWH, Compeer EB, Koning D, Klein M, Amelung FJ, van Baarle D, Boelens JJ, Boes M. Fcγ receptor antigen targeting potentiates cross-presentation by human blood and lymphoid tissue BDCA-3+ dendritic cells. Blood 2012;120:5163-72. [DOI: 10.1182/blood-2012-06-434498] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 5.7] [Reference Citation Analysis]
71 Hakimi Z, Ferchichi S, Aballea S, Odeyemi I, Toumi M, English M, Yakoub-Agha I. Burden of cytomegalovirus disease in allogeneic hematopoietic cell transplant recipients: a national, matched cohort study in an inpatient setting. Curr Res Transl Med 2018;66:95-101. [PMID: 30274738 DOI: 10.1016/j.retram.2018.08.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
72 Lilja AE, Mason PW. The next generation recombinant human cytomegalovirus vaccine candidates—Beyond gB. Vaccine 2012;30:6980-90. [DOI: 10.1016/j.vaccine.2012.09.056] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
73 Griffiths P. Diagnosis of Cytomegalovirus Pneumonitis Following Stem Cell Transplantation: Addressing the Yin and Yang of Molecular Methods. J Infect Dis 2017;215:1493-5. [PMID: 28181647 DOI: 10.1093/infdis/jix049] [Reference Citation Analysis]
74 Schmidt-Hieber M, Bierwirth J, Buchheidt D, Cornely OA, Hentrich M, Maschmeyer G, Schalk E, Vehreschild JJ, Vehreschild MJGT; AGIHO Working Group. Diagnosis and management of gastrointestinal complications in adult cancer patients: 2017 updated evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 2018;97:31-49. [PMID: 29177551 DOI: 10.1007/s00277-017-3183-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
75 Romero PP, Blanco P, Giménez E, Solano C, Navarro D. An update on the management and prevention of cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation. Future Virology 2015;10:113-34. [DOI: 10.2217/fvl.14.102] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
76 Bhat V, Joshi A, Sarode R, Chavan P. Cytomegalovirus infection in the bone marrow transplant patient. World J Transplant 2015; 5(4): 287-291 [PMID: 26722656 DOI: 10.5500/wjt.v5.i4.287] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
77 Solano C, Navarro D. Clinical virology of cytomegalovirus infection following hematopoietic transplantation. Future Virology 2010;5:111-24. [DOI: 10.2217/fvl.09.64] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
78 Pergam SA, Xie H, Sandhu R, Pollack M, Smith J, Stevens-Ayers T, Ilieva V, Kimball LE, Huang ML, Hayes TS, Corey L, Boeckh MJ. Efficiency and risk factors for CMV transmission in seronegative hematopoietic stem cell recipients. Biol Blood Marrow Transplant. 2012;18:1391-1400. [PMID: 22387334 DOI: 10.1016/j.bbmt.2012.02.008] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
79 Ogata M, Satou T, Kawano R, Yoshikawa T, Ikewaki J, Kohno K, Ando T, Miyazaki Y, Ohtsuka E, Saburi Y, Kikuchi H, Saikawa T, Kadota J. High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for Adult T cell leukemia. J Med Virol 2011;83:702-9. [DOI: 10.1002/jmv.22013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
80 Gracia-ahufinger I, Tormo N, Espigado I, Solano C, Urbano-ispizua A, Clari MA, de la Cruz-vicente F, Navarro D, Pérez-romero P. Differences in cytomegalovirus plasma viral loads measured in allogeneic hematopoietic stem cell transplant recipients using two commercial real-time PCR assays. Journal of Clinical Virology 2010;48:142-6. [DOI: 10.1016/j.jcv.2010.03.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
81 Defilipp Z, Chen Y. Strategies and Challenges for Pharmacological Maintenance Therapies after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 2016;22:2134-40. [DOI: 10.1016/j.bbmt.2016.08.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
82 Liang F, Browne DJ, Gray MJ, Gartlan KH, Smith DD, Barnard RT, Hill GR, Corrie SR, Markey KA. Development of a Multiplexed Microsphere PCR for Culture-Free Detection and Gram-Typing of Bacteria in Human Blood Samples. ACS Infect Dis 2018;4:837-44. [DOI: 10.1021/acsinfecdis.7b00277] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
83 Sousa H, Boutolleau D, Ribeiro J, Teixeira AL, Pinho Vaz C, Campilho F, Branca R, Campos A Jr, Baldaque I, Medeiros R. Cytomegalovirus infection in patients who underwent allogeneic hematopoietic stem cell transplantation in Portugal: a five-year retrospective review. Biol Blood Marrow Transplant 2014;20:1958-67. [PMID: 25139217 DOI: 10.1016/j.bbmt.2014.08.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
84 Germi R, Mariette C, Alain S, Lupo J, Thiebaut A, Brion JP, Epaulard O, Saint Raymond C, Malvezzi P, Morand P. Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus. Antiviral Res 2014;101:57-61. [PMID: 24184983 DOI: 10.1016/j.antiviral.2013.10.014] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
85 Jenq RR, van den Brink MR. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer 2010;10:213-21. [PMID: 20168320 DOI: 10.1038/nrc2804] [Cited by in Crossref: 180] [Cited by in F6Publishing: 159] [Article Influence: 15.0] [Reference Citation Analysis]
86 Silva DFLD, Cardoso JF, Silva SPD, Arruda LMF, Medeiros RLF, Moraes MM, Sousa RCM. HCMV UL97 phosphotransferase gene mutations may be associated with antiviral resistance in immunocompromised patients in Belém, PA, Northern Brazil. Rev Soc Bras Med Trop 2018;51:141-5. [PMID: 29768545 DOI: 10.1590/0037-8682-0345-2017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
87 Plotkin SA, Boppana SB. Vaccination against the human cytomegalovirus. Vaccine 2019;37:7437-42. [PMID: 29622379 DOI: 10.1016/j.vaccine.2018.02.089] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 11.3] [Reference Citation Analysis]
88 Costa-Garcia M, Vera A, Moraru M, Vilches C, López-Botet M, Muntasell A. Antibody-mediated response of NKG2Cbright NK cells against human cytomegalovirus. J Immunol 2015;194:2715-24. [PMID: 25667418 DOI: 10.4049/jimmunol.1402281] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 10.6] [Reference Citation Analysis]
89 Alsumali A, Chemaly RF, Graham J, Jiang Y, Merchant S, Miles L, Schelfhout J, Yang J, Tang Y. Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective. J Med Virol 2021;93:3786-94. [PMID: 32844453 DOI: 10.1002/jmv.26462] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
90 Lindsay J, Othman J, Kerridge I, Fay K, Stevenson W, Arthur C, Chen SC, Kong DCM, Pergam SA, Liu C, Slavin MA, Greenwood M. Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Pre-transplant predictors of survival, reactivation, and spontaneous clearance. Transpl Infect Dis 2021;23:e13548. [PMID: 33342000 DOI: 10.1111/tid.13548] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Marty FM, Winston DJ, Chemaly RF, Mullane KM, Shore TB, Papanicolaou GA, Chittick G, Brundage TM, Wilson C, Morrison ME, Foster SA, Nichols WG, Boeckh MJ; SUPPRESS Trial Clinical Study Group. A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Oral Brincidofovir for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2019;25:369-81. [PMID: 30292744 DOI: 10.1016/j.bbmt.2018.09.038] [Cited by in Crossref: 86] [Cited by in F6Publishing: 78] [Article Influence: 21.5] [Reference Citation Analysis]
92 Navarro D, Fernández-Ruiz M, Aguado JM, Sandonís V, Pérez-Romero P. Going beyond serology for stratifying the risk of CMV infection in transplant recipients. Rev Med Virol 2019;29:e2017. [PMID: 30358016 DOI: 10.1002/rmv.2017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
93 Norkin M, Wingard JR. Recent advances in hematopoietic stem cell transplantation. F1000Res 2017;6:870. [PMID: 28663793 DOI: 10.12688/f1000research.11233.1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
94 Hilal T, Slone S, Peterson S, Bodine C, Gul Z. Cytomegalovirus reactivation is associated with a lower rate of early relapse in myeloid malignancies independent of in-vivo T cell depletion strategy. Leuk Res 2017;57:37-44. [PMID: 28279876 DOI: 10.1016/j.leukres.2017.02.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
95 Krause PR, Bialek SR, Boppana SB, Griffiths PD, Laughlin CA, Ljungman P, Mocarski ES, Pass RF, Read JS, Schleiss MR, Plotkin SA. Priorities for CMV vaccine development. Vaccine 2013;32:4-10. [PMID: 24129123 DOI: 10.1016/j.vaccine.2013.09.042] [Cited by in Crossref: 106] [Cited by in F6Publishing: 95] [Article Influence: 11.8] [Reference Citation Analysis]
96 Tengsupakul S, Birge ND, Bendel CM, Reed RC, Bloom BA, Hernandez N, Schleiss MR. Asymptomatic DNAemia heralds CMV-associated NEC: case report, review, and rationale for preemption. Pediatrics 2013;132:e1428-34. [PMID: 24144715 DOI: 10.1542/peds.2013-0087] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
97 Al-Badr AA, Ajarim TDS. Ganciclovir. Profiles Drug Subst Excip Relat Methodol 2018;43:1-208. [PMID: 29678260 DOI: 10.1016/bs.podrm.2017.12.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
98 Kaul KL, Sabatini LM, Tsongalis GJ, Caliendo AM, Olsen RJ, Ashwood ER, Bale S, Benirschke R, Carlow D, Funke BH, Grody WW, Hayden RT, Hegde M, Lyon E, Murata K, Pessin M, Press RD, Thomson RB. The Case for Laboratory Developed Procedures: Quality and Positive Impact on Patient Care. Acad Pathol 2017;4:2374289517708309. [PMID: 28815200 DOI: 10.1177/2374289517708309] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
99 Breuer S, Rauch M, Matthes-Martin S, Lion T. Molecular diagnosis and management of viral infections in hematopoietic stem cell transplant recipients. Mol Diagn Ther 2012;16:63-77. [PMID: 22497528 DOI: 10.1007/BF03256431] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
100 Pérez-Bercoff L, Vudattu NK, Byrareddy SN, Mattsson J, Maeurer M, Ljungman P. Reduced IL-7 responsiveness defined by signal transducer and activator of transcription 5 phosphorylation in T cells may be a marker for increased risk of developing cytomegalovirus disease in patients after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014;20:128-32. [PMID: 24140122 DOI: 10.1016/j.bbmt.2013.10.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
101 Gagelmann N, Ljungman P, Styczynski J, Kröger N. Comparative Efficacy and Safety of Different Antiviral Agents for Cytomegalovirus Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant 2018;24:2101-9. [PMID: 29777868 DOI: 10.1016/j.bbmt.2018.05.017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
102 Barrett JA. T-cell therapy for viral infections following transplantation: why stop at three viruses? Mol Ther 2012;20:1487-8. [PMID: 22850720 DOI: 10.1038/mt.2012.138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
103 Ariza-Heredia EJ, Nesher L, Chemaly RF. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett. 2014;342:1-8. [PMID: 24041869 DOI: 10.1016/j.canlet.2013.09.004] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 11.8] [Reference Citation Analysis]
104 Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, Young JA, Rodriguez T, Maertens J, Schmitt M. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011;11:284-292. [PMID: 21414843 DOI: 10.1016/s1473-3099(11)70024-x] [Cited by in Crossref: 243] [Cited by in F6Publishing: 86] [Article Influence: 22.1] [Reference Citation Analysis]
105 Patel HD, Nikitin P, Gesner T, Lin JJ, Barkan DT, Ciferri C, Carfi A, Akbarnejad Yazdi T, Skewes-Cox P, Wiedmann B, Jarousse N, Zhong W, Feire A, Hebner CM. In Vitro Characterization of Human Cytomegalovirus-Targeting Therapeutic Monoclonal Antibodies LJP538 and LJP539. Antimicrob Agents Chemother 2016;60:4961-71. [PMID: 27270290 DOI: 10.1128/AAC.00382-16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
106 Ishii K, Onishi Y, Miyamura N, Fukuhara N, Ishizawa K, Nakanishi M, Ohnaka S, Miyasaka T, Kanno E, Kawakami K, Harigae H, Kaku M. Development and evaluation of a quantitative assay detecting cytomegalovirus transcripts for preemptive therapy in allogeneic hematopoietic stem cell transplant recipients. J Med Virol 2017;89:1265-73. [DOI: 10.1002/jmv.24775] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
107 Maertens J, Lyon S. Optimizing the management of cytomegalovirus infection in transplant patients. Future Virology 2018;13:765-8. [DOI: 10.2217/fvl-2018-0142] [Reference Citation Analysis]
108 Bontant T, Sedlaçek P, Balduzzi A, Gaspar B, Cesaro S, Einsele H, Peters C, Dalle J. Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the Inborn Errors, Infectious Diseases and Pediatric Diseases Working Parties of EBMT. Bone Marrow Transplant 2014;49:276-9. [DOI: 10.1038/bmt.2013.164] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
109 El-Asmar J, Kharfan-Dabaja MA, Ayala E. Acute pericarditis and tamponade from Coxsackie B3 in an adult Hematopoietic-Cell-Allograft recipient: A rare but potentially serious complication. Hematol Oncol Stem Cell Ther 2016;9:82-5. [PMID: 26183671 DOI: 10.1016/j.hemonc.2015.06.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
110 Tremblay MA, Rodrigue MA, Deschênes L, Boivin G, Longtin J. Cytomegalovirus quantification in plasma with Abbott RealTime CMV and Roche Cobas Amplicor CMV assays. J Virol Methods 2015;225:1-3. [PMID: 26341060 DOI: 10.1016/j.jviromet.2015.08.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
111 Pötzsch S, Spindler N, Wiegers AK, Fisch T, Rücker P, Sticht H, Grieb N, Baroti T, Weisel F, Stamminger T, Martin-Parras L, Mach M, Winkler TH. B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog 2011;7:e1002172. [PMID: 21852946 DOI: 10.1371/journal.ppat.1002172] [Cited by in Crossref: 103] [Cited by in F6Publishing: 96] [Article Influence: 9.4] [Reference Citation Analysis]
112 Full F, Lehner M, Thonn V, Goetz G, Scholz B, Kaufmann KB, Mach M, Abken H, Holter W, Ensser A. T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor. J Virol 2010;84:4083-8. [PMID: 20147393 DOI: 10.1128/JVI.02117-09] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
113 Hayden RT, Preiksaitis J, Tong Y, Pang X, Sun Y, Tang L, Cook L, Pounds S, Fryer J, Caliendo AM. Commutability of the First World Health Organization International Standard for Human Cytomegalovirus. J Clin Microbiol 2015;53:3325-33. [PMID: 26269622 DOI: 10.1128/JCM.01495-15] [Cited by in Crossref: 65] [Cited by in F6Publishing: 18] [Article Influence: 9.3] [Reference Citation Analysis]
114 Marr KA. Delayed opportunistic infections in hematopoietic stem cell transplantation patients: a surmountable challenge. Hematology Am Soc Hematol Educ Program 2012;2012:265-70. [PMID: 23233590 DOI: 10.1182/asheducation-2012.1.265] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
115 López-botet M, Muntasell A, Vilches C. The CD94/NKG2C+ NK-cell subset on the edge of innate and adaptive immunity to human cytomegalovirus infection. Seminars in Immunology 2014;26:145-51. [DOI: 10.1016/j.smim.2014.03.002] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 9.1] [Reference Citation Analysis]
116 Suganda S, Tang L, Carr J, Sun Y, Pounds S, Hayden R. Comparative evaluation of whole blood versus plasma for quantitative detection of cytomegalovirus using an automated system. Diagnostic Microbiology and Infectious Disease 2016;85:23-5. [DOI: 10.1016/j.diagmicrobio.2015.12.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
117 Shigle TL, Handy VW, Chemaly RF. Letermovir and its role in the prevention of cytomegalovirus infection in seropositive patients receiving an allogeneic hematopoietic cell transplant. Ther Adv Hematol 2020;11:2040620720937150. [PMID: 32637057 DOI: 10.1177/2040620720937150] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
118 Chan TS, Cheng SS, Chen WT, Hsu DC, Chau RW, Kang SH, Alsumali A, Kwong YL. Cost-effectiveness of letermovir as cytomegalovirus prophylaxis in adult recipients of allogeneic hematopoietic stem cell transplantation in Hong Kong. J Med Econ 2020;23:1485-92. [PMID: 33155494 DOI: 10.1080/13696998.2020.1843321] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
119 Ruenroengbun N, Numthavaj P, Sapankaew T, Chaiyakittisopon K, Ingsathit A, Mckay GJ, Attia J, Thakkinstian A. Efficacy and safety of conventional antiviral agents in preventive strategies for cytomegalovirus infection after kidney transplantation: a systematic review and network meta-analysis. Transpl Int 2021. [PMID: 34580930 DOI: 10.1111/tri.14122] [Reference Citation Analysis]
120 Peric Z, Wilson J, Durakovic N, Ostojic A, Desnica L, Vranjes VR, Marekovic I, Serventi-Seiwerth R, Vrhovac R. Early human cytomegalovirus reactivation is associated with lower incidence of relapse of myeloproliferative disorders after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2018;53:1450-6. [PMID: 29662245 DOI: 10.1038/s41409-018-0172-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
121 Ding Y, Ru Y, Song T, Guo L, Zhang X, Zhu J, Li C, Jin Z, Huang H, Tu Y, Xu M, Xu Y, Chen J, Wu D. Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes : EBV and CMV reactivation post allo-HCT in NHL. Ann Hematol 2021;100:2773-85. [PMID: 34480615 DOI: 10.1007/s00277-021-04642-5] [Reference Citation Analysis]
122 Wolfe D, Zhao Q, Siegel E, Puto M, Murphy D, Roddy J, Efebera Y, Tossey J. Letermovir Prophylaxis and Cytomegalovirus Reactivation in Adult Hematopoietic Cell Transplant Recipients with and without Acute Graft Versus Host Disease. Cancers (Basel) 2021;13:5572. [PMID: 34771734 DOI: 10.3390/cancers13215572] [Reference Citation Analysis]
123 Flinsenberg TW, Spel L, Jansen M, Koning D, de Haar C, Plantinga M, Scholman R, van Loenen MM, Nierkens S, Boon L, van Baarle D, Heemskerk MH, Boelens JJ, Boes M. Cognate CD4 T-cell licensing of dendritic cells heralds anti-cytomegalovirus CD8 T-cell immunity after human allogeneic umbilical cord blood transplantation. J Virol 2015;89:1058-69. [PMID: 25378489 DOI: 10.1128/JVI.01850-14] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
124 Lazzarotto T, Chiereghin A, Piralla A, Piccirilli G, Girello A, Campanini G, Gabrielli L, Costa C, Prete A, Bonifazi F, Busca A, Cairoli R, Colombo AA, Zecca M, Sidoti F, Bianco G, Paba P, Perno CF, Cavallo R, Baldanti F. Cytomegalovirus and Epstein-Barr Virus DNA Kinetics in Whole Blood and Plasma of Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Biology of Blood and Marrow Transplantation 2018;24:1699-706. [DOI: 10.1016/j.bbmt.2018.03.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
125 Damlaj M, Khalid F, Alahmari B, Alaskar A, Ghazi S, Johani S, AlSaedy A, Bosaeed M, Alhejazi A, Al-Zahrani M. Optimal pre-emptive cytomegalovirus therapy threshold in a patient population with high prevalence of seropositive status. Curr Res Transl Med 2020;68:131-7. [PMID: 32620466 DOI: 10.1016/j.retram.2020.04.005] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
126 Franck B, Autmizguine J, Marquet P, Ovetchkine P, Woillard JB. Pharmacokinetics, Pharmacodynamics, and Therapeutic Drug Monitoring of Valganciclovir and Ganciclovir in Transplantation. Clin Pharmacol Ther 2021. [PMID: 34596243 DOI: 10.1002/cpt.2431] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Liu H, Zheng X, Zhang C, Xie J, Gao B, Shao J, Yang Y, Wang H, Yan J. Outcomes of haploidentical bone marrow transplantation in patients with severe aplastic anemia-II that progressed from non-severe acquired aplastic anemia. Front Med 2021. [PMID: 34170455 DOI: 10.1007/s11684-020-0807-4] [Reference Citation Analysis]
128 Tan BH. Cytomegalovirus Treatment. Curr Treat Options Infect Dis 2014;6:256-70. [PMID: 25999800 DOI: 10.1007/s40506-014-0021-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
129 Cho SY, Lee DG, Kim HJ. Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy. Int J Mol Sci 2019;20:E2666. [PMID: 31151230 DOI: 10.3390/ijms20112666] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
130 Malagola M, Pollara C, Polverelli N, Zollner T, Bettoni D, Gandolfi L, Gramegna D, Morello E, Turra A, Corbellini S, Signorini L, Moioli G, Bernardi S, Zanaglio C, Farina M, Testa TE, Caruso A, Russo D. Advances in CMV Management: A Single Center Real-Life Experience. Front Cell Dev Biol 2020;8:534268. [PMID: 33195184 DOI: 10.3389/fcell.2020.534268] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
131 Krawczyk A, Ackermann J, Goitowski B, Trenschel R, Ditschkowski M, Timm J, Ottinger H, Beelen DW, Grüner N, Fiedler M. Assessing the risk of CMV reactivation and reconstitution of antiviral immune response post bone marrow transplantation by the QuantiFERON-CMV-assay and real time PCR. J Clin Virol 2018;99-100:61-6. [PMID: 29331844 DOI: 10.1016/j.jcv.2018.01.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
132 Jorge L, Torres D, Languasco A, Rodríguez P, Bonvehí P, Temporiti E, Relloso S, Videla C, Herrera F. Clinical Usefulness of Bronchoalveolar Lavage in the Management of Pulmonary Infiltrates in Adults with Hematological Malignancies and Stem Cell Transplantation. Mediterr J Hematol Infect Dis 2020;12:e2020025. [PMID: 32395214 DOI: 10.4084/MJHID.2020.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
133 Nishihori T, Shaheen M, El-Asmar J, Aljurf M, Kharfan-Dabaja MA. Therapeutic strategies for cytomegalovirus in allogeneic hematopoietic cell transplantation. Immunotherapy 2015;7:1059-71. [PMID: 26507225 DOI: 10.2217/imt.15.70] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
134 Hodowanec AC, Pikis A, Komatsu TE, Sampson MR, Younis IR, O'Rear JJ, Singer ME. Treatment and Prevention of CMV Disease in Transplant Recipients: Current Knowledge and Future Perspectives. J Clin Pharmacol 2019;59:784-98. [PMID: 30586161 DOI: 10.1002/jcph.1363] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
135 Cromer D, Tey SK, Khanna R, Davenport MP. Estimating cytomegalovirus growth rates by using only a single point. J Virol 2013;87:3376-81. [PMID: 23302875 DOI: 10.1128/JVI.02821-12] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
136 Basso S, Compagno F, Zelini P, Giorgiani G, Boghen S, Bergami E, Bagnarino J, Siciliano M, Del Fante C, Luppi M, Zecca M, Comoli P. Harnessing T Cells to Control Infections After Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 2020;11:567531. [PMID: 33178192 DOI: 10.3389/fimmu.2020.567531] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
137 Frenzel K, Lehmann J, Krüger DH, Martin-Parras L, Uharek L, Hofmann J. Combination of immunoglobulins and natural killer cells in the context of CMV and EBV infection. Med Microbiol Immunol 2014;203:115-23. [PMID: 24337366 DOI: 10.1007/s00430-013-0321-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
138 Giest S, McWhinnie A, Lefranc MP, Little AM, Grace S, Mackinnon S, Madrigal JA, Travers PJ. Cytomegalovirus-specific CD8+ T cells targeting different peptide/HLA combinations demonstrate varying T-cell receptor diversity. Immunology 2012;135:27-39. [PMID: 22044339 DOI: 10.1111/j.1365-2567.2011.03508.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
139 Chiba A, Nakamura F, Nakazaki K, Kurokawa M. Cytomegalovirus antigenemia and end-organ disease in Japanese patients treated with bendamustine. Leuk Lymphoma 2018;59:749-51. [PMID: 28697686 DOI: 10.1080/10428194.2017.1347928] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
140 Nombela-Arrieta C, Isringhausen S. The Role of the Bone Marrow Stromal Compartment in the Hematopoietic Response to Microbial Infections. Front Immunol 2016;7:689. [PMID: 28163704 DOI: 10.3389/fimmu.2016.00689] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
141 Fereidouni M, Derakhshani A, Exley MA. iNKT cells and hematopoietic stem cell transplantation: Two-phase activation of iNKT cells may improve outcome. Clin Immunol 2019;207:43-8. [PMID: 31128279 DOI: 10.1016/j.clim.2019.05.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
142 Camargo JF, Wieder ED, Kimble E, Benjamin CL, Kolonias DS, Kwon D, Chen XS, Komanduri KV. Deep functional immunophenotyping predicts risk of cytomegalovirus reactivation after hematopoietic cell transplantation. Blood 2019;133:867-77. [PMID: 30573634 DOI: 10.1182/blood-2018-10-878918] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
143 Vakil E, Evans SE. Viral Pneumonia in Patients with Hematologic Malignancy or Hematopoietic Stem Cell Transplantation. Clin Chest Med 2017;38:97-111. [PMID: 28159165 DOI: 10.1016/j.ccm.2016.11.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
144 Lugthart G, van Ostaijen-ten Dam MM, Jol - van der Zijde CM, van Holten TC, Kester MG, Heemskerk MH, Bredius RG, van Tol MJ, Lankester AC. Early Cytomegalovirus Reactivation Leaves a Specific and Dynamic Imprint on the Reconstituting T Cell Compartment Long-Term after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2014;20:655-61. [DOI: 10.1016/j.bbmt.2014.01.018] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
145 Piukovics K, Terhes G, Gurbity-Pálfi T, Bereczki Á, Rárosi F, Deák J, Borbényi Z, Urbán E. Cytomegalovirus infection in patients with haematological diseases and after autologous stem cell transplantation as consolidation: a single-centre study. Ann Hematol 2017;96:125-31. [PMID: 27730340 DOI: 10.1007/s00277-016-2831-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
146 Lam S, Boan P, Polistena P, Cannell P, Cooney J, Wright M, Purtill D. High dose valaciclovir to prevent cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients. Transpl Infect Dis 2021;:e13633. [PMID: 33978289 DOI: 10.1111/tid.13633] [Reference Citation Analysis]
147 Verduyn Lunel FM, Raymakers R, van Dijk A, van der Wagen L, Minnema MC, Kuball J. Cytomegalovirus Status and the Outcome of T Cell-Replete Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2016;22:1883-7. [PMID: 27470287 DOI: 10.1016/j.bbmt.2016.07.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
148 Servais S, Dumontier N, Biard L, Schnepf N, Resche-Rigon M, Peffault de Latour R, Scieux C, Robin M, Meunier M, Xhaard A, Sicre de Fontbrune F, Le Goff J, Socié G, Simon F, Mazeron MC. Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status. Clin Microbiol Infect 2016;22:289.e1-7. [PMID: 26627339 DOI: 10.1016/j.cmi.2015.11.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
149 Mills AM, Guo FP, Copland AP, Pai RK, Pinsky BA. A comparison of CMV detection in gastrointestinal mucosal biopsies using immunohistochemistry and PCR performed on formalin-fixed, paraffin-embedded tissue. Am J Surg Pathol. 2013;37:995-1000. [PMID: 23648457 DOI: 10.1097/pas.0b013e31827fcc33] [Cited by in Crossref: 55] [Cited by in F6Publishing: 19] [Article Influence: 6.1] [Reference Citation Analysis]
150 Göhring K, Hamprecht K, Jahn G. Antiviral Drug- and Multidrug Resistance in Cytomegalovirus Infected SCT Patients. Comput Struct Biotechnol J 2015;13:153-9. [PMID: 25750703 DOI: 10.1016/j.csbj.2015.01.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
151 Brey CU, Proff J, Teufert N, Salzer B, Brozy J, Münz M, Pendzialek J, Ensser A, Holter W, Lehner M. A gB/CD3 bispecific BiTE antibody construct for targeting Human Cytomegalovirus-infected cells. Sci Rep 2018;8:17453. [PMID: 30487534 DOI: 10.1038/s41598-018-36055-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
152 El Chaer F, Shah DP, Chemaly RF. How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients. Blood 2016;128:2624-36. [PMID: 27760756 DOI: 10.1182/blood-2016-06-688432] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 13.0] [Reference Citation Analysis]
153 Arcuri LJ, Schirmer M, Colares M, Maradei S, Tavares R, Moreira MCR, Araujo RDC, Lerner D, Pacheco AGF. Impact of Anti-CMV IgG Titers and CD34 Count Prior to Hematopoietic Stem Cell Transplantation from Alternative Donors on CMV reactivation. Biology of Blood and Marrow Transplantation 2020;26:e275-9. [DOI: 10.1016/j.bbmt.2020.07.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
154 Pande A, Dubberke ER. Cytomegalovirus Infections of the Stem Cell Transplant Recipient and Hematologic Malignancy Patient. Infectious Disease Clinics of North America 2019;33:485-500. [DOI: 10.1016/j.idc.2019.02.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
155 Wingard JR, Hsu J, Hiemenz JW. Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. Hematol Oncol Clin North Am 2011;25:101-16. [PMID: 21236393 DOI: 10.1016/j.hoc.2010.11.008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.3] [Reference Citation Analysis]
156 Foolad F, Aitken SL, Chemaly RF. Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients. Expert Rev Clin Pharmacol 2018;11:931-41. [PMID: 30004790 DOI: 10.1080/17512433.2018.1500897] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
157 Chevillotte M, von Einem J, Meier BM, Lin F, Kestler HA, Mertens T. A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes. Antiviral Research 2010;85:318-27. [DOI: 10.1016/j.antiviral.2009.10.004] [Cited by in Crossref: 56] [Cited by in F6Publishing: 51] [Article Influence: 4.7] [Reference Citation Analysis]
158 Park SY, Lee SO, Choi SH, Kim YS, Woo JH, Baek S, Sung H, Kim MN, Kim DY, Lee JH, Lee JH, Lee KH, Kim SH. Efficacy and safety of low-dose ganciclovir preemptive therapy in allogeneic haematopoietic stem cell transplant recipients compared with conventional-dose ganciclovir: a prospective observational study. J Antimicrob Chemother 2012;67:1486-92. [PMID: 22354954 DOI: 10.1093/jac/dks043] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
159 Tan SK, Waggoner JJ, Pinsky BA. Cytomegalovirus load at treatment initiation is predictive of time to resolution of viremia and duration of therapy in hematopoietic cell transplant recipients. J Clin Virol 2015;69:179-83. [PMID: 26209403 DOI: 10.1016/j.jcv.2015.06.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.1] [Reference Citation Analysis]
160 Hemsing AL, Gjertsen BT, Spetalen S, Helgeland L, Reikvam H. Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation. SAGE Open Med Case Rep 2021;9:2050313X20988413. [PMID: 33628448 DOI: 10.1177/2050313X20988413] [Reference Citation Analysis]
161 Kharfan-Dabaja MA, Nishihori T. Vaccine therapy for cytomegalovirus in the setting of allogeneic hematopoietic cell transplantation. Expert Rev Vaccines 2015;14:341-50. [PMID: 25468066 DOI: 10.1586/14760584.2015.989990] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
162 Doney K, Gooley TA, Deeg HJ, Flowers ME, Storb R, Appelbaum FR. Allogeneic hematopoietic cell transplantation with full-intensity conditioning for adult acute lymphoblastic leukemia: results from a single center, 1998-2006. Biol Blood Marrow Transplant 2011;17:1187-95. [PMID: 21182975 DOI: 10.1016/j.bbmt.2010.12.699] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
163 Tan PL, Lim LM, Khanlian C, Villegas MS. A single-center experience of cytomegalovirus infections in Asian pediatric patients undergoing allogeneic hematopoietic stem cell transplant for leukemia in Singapore. Transpl Infect Dis 2014;16:556-60. [PMID: 24862456 DOI: 10.1111/tid.12238] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
164 Pillet S, Bourlet T, Pozzetto B. Comparative evaluation of the QIAsymphony RGQ system with the easyMAG/R-gene combination for the quantitation of cytomegalovirus DNA load in whole blood. Virol J 2012;9:231. [PMID: 23046712 DOI: 10.1186/1743-422X-9-231] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
165 Zhao XY, Luo XY, Yu XX, Zhao XS, Han TT, Chang YJ, Huo MR, Xu LP, Zhang XH, Liu KY, Li D, Jiang ZF, Huang XJ. Recipient-donor KIR ligand matching prevents CMV reactivation post-haploidentical T cell-replete transplantation. Br J Haematol 2017;177:766-81. [PMID: 28466469 DOI: 10.1111/bjh.14622] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
166 Olbrich H, Theobald SJ, Slabik C, Gerasch L, Schneider A, Mach M, Shum T, Mamonkin M, Stripecke R. Adult and Cord Blood-Derived High-Affinity gB-CAR-T Cells Effectively React Against Human Cytomegalovirus Infections. Hum Gene Ther 2020;31:423-39. [PMID: 32159399 DOI: 10.1089/hum.2019.149] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
167 Krishna BA, Spiess K, Poole EL, Lau B, Voigt S, Kledal TN, Rosenkilde MM, Sinclair JH. Targeting the latent cytomegalovirus reservoir with an antiviral fusion toxin protein. Nat Commun 2017;8:14321. [PMID: 28148951 DOI: 10.1038/ncomms14321] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 8.0] [Reference Citation Analysis]
168 Gantt S, Carlsson J, Ikoma M, Gachelet E, Gray M, Geballe AP, Corey L, Casper C, Lagunoff M, Vieira J. The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro. Antimicrob Agents Chemother 2011;55:2696-703. [PMID: 21402841 DOI: 10.1128/AAC.01295-10] [Cited by in Crossref: 56] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
169 Bednar C, Ensser A. CARs-A New Perspective to HCMV Treatment. Viruses 2021;13:1563. [PMID: 34452428 DOI: 10.3390/v13081563] [Reference Citation Analysis]
170 Baghban A, Malinis M. Ganciclovir and foscarnet dual-therapy for cytomegalovirus encephalitis: A case report and review of the literature. J Neurol Sci 2018;388:28-36. [PMID: 29627026 DOI: 10.1016/j.jns.2018.02.029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
171 Paolino K, Sande J, Perez E, Loechelt B, Jantausch B, Painter W, Anderson M, Tippin T, Lanier ER, Fry T, DeBiasi RL. Eradication of disseminated adenovirus infection in a pediatric hematopoietic stem cell transplantation recipient using the novel antiviral agent CMX001. J Clin Virol 2011;50:167-70. [PMID: 21094081 DOI: 10.1016/j.jcv.2010.10.016] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 4.8] [Reference Citation Analysis]
172 Ardura MI. Overview of Infections Complicating Pediatric Hematopoietic Cell Transplantation. Infect Dis Clin North Am 2018;32:237-52. [PMID: 29406976 DOI: 10.1016/j.idc.2017.11.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
173 Michaelis M, Paulus C, Löschmann N, Dauth S, Stange E, Doerr HW, Nevels M, Cinatl J Jr. The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication. Cell Mol Life Sci 2011;68:1079-90. [PMID: 20803231 DOI: 10.1007/s00018-010-0510-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
174 Navarro D. Expanding role of cytomegalovirus as a human pathogen: Cytomegalovirus and Human Disease. J Med Virol 2016;88:1103-12. [DOI: 10.1002/jmv.24450] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
175 Pastore D, Delia M, Mestice A, Perrone T, Carluccio P, Gaudio F, Giordano A, Rossi AR, Ricco A, Leo M, Liso V, Specchia G. Recovery of CMV-Specific CD8+ T Cells and Tregs after Allogeneic Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2011;17:550-7. [DOI: 10.1016/j.bbmt.2010.04.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
176 Gabanti E, Borsani O, Caldera D, Colombo AA, Ferretti VV, Alessandrino EP, Gerna G, Bernasconi P, Lilleri D. Early T cell reconstitution and cytokine profile may help to guide a personalized management of human cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. J Clin Virol 2021;135:104734. [PMID: 33476929 DOI: 10.1016/j.jcv.2021.104734] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Takenaka K, Onishi Y, Mori T, Hirakawa T, Tada Y, Uchida N, Kobayashi T, Kanda Y, Ozawa Y, Ota S, Iida H, Fukushima K, Kimua T, Fukuda T, Atsuta Y, Matsuto K, Yamazaki H, Nakasone H. Negative Impact of Cytomegalovirus Reactivation on Survival in Adult Patients with Aplastic Anemia after an Allogeneic Hematopoietic Stem Cell Transplantation: A Report from Transplantation-Related Complication and Adult Aplastic Anemia Working Groups of the Japan Society for Hematopoietic Cell Transplantation. Transplant Cell Ther 2021;27:82.e1-8. [PMID: 33039517 DOI: 10.1016/j.bbmt.2020.10.001] [Reference Citation Analysis]
178 Huntley D, Talaya A, Giménez E, Martínez A, Hernández-Boluda JC, Hernani R, Torres I, Alberola J, Albert E, Piñana JL, Solano C, Navarro D. Features of Cytomegalovirus DNAemia Blips in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Implications for Optimization of Preemptive Antiviral Therapy Strategies. Biol Blood Marrow Transplant 2020;26:972-7. [PMID: 32007638 DOI: 10.1016/j.bbmt.2020.01.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
179 de la Cámara R. CMV in Hematopoietic Stem Cell Transplantation. Mediterr J Hematol Infect Dis 2016;8:e2016031. [PMID: 27413524 DOI: 10.4084/MJHID.2016.031] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 5.5] [Reference Citation Analysis]
180 Kang KW, Lee JH, Choi JS, Lee SR, Park Y, Kim BS, Kim I. Spontaneous resolution of post-transplant localized cytomegalovirus lymphadenitis mimicking tumor recurrence. Transpl Infect Dis 2014;16:676-80. [PMID: 24965019 DOI: 10.1111/tid.12254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
181 Stuehler C, Stüssi G, Halter J, Nowakowska J, Schibli A, Battegay M, Dirks J, Passweg J, Heim D, Rovo A, Kalberer C, Bucher C, Weisser M, Dumoulin A, Hirsch HH, Khanna N. Combination therapy for multidrug-resistant cytomegalovirus disease. Transpl Infect Dis 2015;17:751-5. [PMID: 26432076 DOI: 10.1111/tid.12435] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
182 Pillet S, Pozzetto B, Jarlot C, Paul S, Roblin X. Management of cytomegalovirus infection in inflammatory bowel diseases. Dig Liver Dis. 2012;44:541-548. [PMID: 22538204 DOI: 10.1016/j.dld.2012.03.018] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
183 Xiao H, Luo Y, Lai X, Fu S, Shi J, Tan Y, He J, Xie W, Zheng W, Wang LM, Zhang L, Liu L, Ye X, Yu X, Cai Z, Lin M, Huang H. Genetic variations in T-cell activation and effector pathways modulate alloimmune responses after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies. Haematologica 2012;97:1804-12. [PMID: 22733023 DOI: 10.3324/haematol.2012.066159] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
184 Melendez-Munoz R, Marchalik R, Jerussi T, Dimitrova D, Nussenblatt V, Beri A, Rai K, Wilder JS, Barrett AJ, Battiwalla M, Childs RW, Fitzhugh CD, Fowler DH, Fry TJ, Gress RE, Hsieh MM, Ito S, Kang EM, Pavletic SZ, Shah NN, Tisdale JF, Gea-Banacloche J, Kanakry CG, Kanakry JA. Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution. Biol Blood Marrow Transplant 2019;25:577-86. [PMID: 30342913 DOI: 10.1016/j.bbmt.2018.10.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
185 Takenaka K, Nagafuji K, Takase K, Kamimura T, Mori Y, Ito Y, Nishi Y, Henzan H, Kato K, Harada N, Eto T, Miyamoto T, Teshima T, Akashi K. Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients. Int J Hematol 2012;96:94-100. [DOI: 10.1007/s12185-012-1087-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
186 Boeckh M, Geballe AP. Cytomegalovirus: pathogen, paradigm, and puzzle. J Clin Invest. 2011;121:1673-1680. [PMID: 21659716 DOI: 10.1172/jci45449] [Cited by in Crossref: 211] [Cited by in F6Publishing: 113] [Article Influence: 19.2] [Reference Citation Analysis]
187 Haidar G, Boeckh M, Singh N. Cytomegalovirus Infection in Solid Organ and Hematopoietic Cell Transplantation: State of the Evidence. J Infect Dis 2020;221:S23-31. [PMID: 32134486 DOI: 10.1093/infdis/jiz454] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
188 Mårtensson T, Szakos A, Mellgren K, Toporski J, Arvidson J, Casswall TH, Gustafsson B. Choice of Endoscopic Procedure in Children With Clinically Suspected Gastrointestinal Graft-versus-host Disease. Journal of Pediatric Gastroenterology & Nutrition 2018;66:744-50. [DOI: 10.1097/mpg.0000000000001776] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
189 Mikulska M, Raiola AM, Bruzzi P, Varaldo R, Annunziata S, Lamparelli T, Frassoni F, Tedone E, Galano B, Bacigalupo A, Viscoli C. CMV infection after transplant from cord blood compared to other alternative donors: the importance of donor-negative CMV serostatus. Biol Blood Marrow Transplant 2012;18:92-9. [PMID: 21689774 DOI: 10.1016/j.bbmt.2011.05.015] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
190 Zama D, Masetti R, Vendemini F, Di Donato F, Morelli A, Prete A, Pession A. Clinical effectiveness of early treatment with hyperbaric oxygen therapy for severe late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation in pediatric patients. Pediatr Transplant 2013;17:86-91. [PMID: 23230825 DOI: 10.1111/petr.12031] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
191 Zhao XT, Zhou DQ, Wu S, Chen YW, Shao Y, Zhang J, Xia CS, Wang KP, Yang H, Wan J, Yu B, Zhang Z, Zhang W. Genotyping cytomegalovirus UL97 mutations by high-resolution melting analysis with unlabeled probe. Arch Virol 2012;157:475-81. [PMID: 22205145 DOI: 10.1007/s00705-011-1173-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
192 Vinuesa V, Bracho MA, Albert E, Solano C, Torres-Puente M, Giménez E, González-Candelas F, Navarro D. The impact of virus population diversity on the dynamics of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. J Gen Virol 2017;98:2530-42. [PMID: 28874227 DOI: 10.1099/jgv.0.000916] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
193 Schulz S. [Experimental immunopathology and molecular pathology of infections]. Pathologe 2010;31 Suppl 2:167-9. [PMID: 20652809 DOI: 10.1007/s00292-010-1327-9] [Reference Citation Analysis]
194 Zhang L, Tao J, Wen Y, Li L, Wu X, Li X, Li X. Cytomegalovirus infection in patients with lupus nephritis: clinical and laboratory features and therapeutic considerations. Clin Exp Med 2017;17:467-75. [DOI: 10.1007/s10238-017-0456-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
195 Juric-Sekhar G, Upton MP, Swanson PE, Westerhoff M. Cytomegalovirus (CMV) in gastrointestinal mucosal biopsies: should a pathologist perform CMV immunohistochemistry if the clinician requests it? Hum Pathol. 2017;60:11-15. [PMID: 27666768 DOI: 10.1016/j.humpath.2016.09.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
196 Wittmann Dayagi T, Sherman G, Bielorai B, Adam E, Besser MJ, Shimoni A, Nagler A, Toren A, Jacoby E, Avigdor A. Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells. Leuk Lymphoma 2021;62:1692-701. [PMID: 33563059 DOI: 10.1080/10428194.2021.1881506] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
197 Andersson TM, Lambert PC, Derolf AR, Kristinsson SY, Eloranta S, Landgren O, Björkholm M, Dickman PW. Temporal trends in the proportion cured among adults diagnosed with acute myeloid leukaemia in Sweden 1973-2001, a population-based study. Br J Haematol 2010;148:918-24. [PMID: 19995394 DOI: 10.1111/j.1365-2141.2009.08026.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
198 Gassas A, Craig-barnes H, Dell SD, Cox P, Schechter T, Doyle J, Sung L, Egeler M, Palaniyar N. Severe lung injury and lung biopsy in children post-hematopoietic stem cell transplantation: The differences between allogeneic and autologous transplantation. Pediatr Transplantation 2013;17:278-84. [DOI: 10.1111/petr.12060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
199 Freed DC, Tang Q, Tang A, Li F, He X, Huang Z, Meng W, Xia L, Finnefrock AC, Durr E, Espeseth AS, Casimiro DR, Zhang N, Shiver JW, Wang D, An Z, Fu TM. Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine. Proc Natl Acad Sci U S A 2013;110:E4997-5005. [PMID: 24297878 DOI: 10.1073/pnas.1316517110] [Cited by in Crossref: 97] [Cited by in F6Publishing: 93] [Article Influence: 10.8] [Reference Citation Analysis]
200 Leen AM, Heslop HE, Brenner MK. Antiviral T-cell therapy. Immunol Rev 2014;258:12-29. [PMID: 24517423 DOI: 10.1111/imr.12138] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
201 Whited LK, Handy VW, Hosing C, Chow E. Incidence of viral and fungal complications after utilization of alternative donor sources in hematopoietic cell transplantation. Pharmacotherapy 2020;40:773-87. [PMID: 32497299 DOI: 10.1002/phar.2433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
202 Cardeñoso L, Pinsky BA, Lautenschlager I, Aslam S, Cobb B, Vilchez RA, Hirsch HH. CMV antigenemia and quantitative viral load assessments in hematopoietic stem cell transplant recipients. Journal of Clinical Virology 2013;56:108-12. [DOI: 10.1016/j.jcv.2012.10.001] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
203 Halfon P, Berger P, Khiri H, Martineau A, Pénaranda G, Merlin M, Faucher C. Algorithm based on CMV kinetics DNA viral load for preemptive therapy initiation after hematopoietic cell transplantation. J Med Virol 2011;83:490-5. [DOI: 10.1002/jmv.21996] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
204 Zhou X, Jin N, Chen B. Human cytomegalovirus infection: A considerable issue following allogeneic hematopoietic stem cell transplantation. Oncol Lett 2021;21:318. [PMID: 33692850 DOI: 10.3892/ol.2021.12579] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
205 Dahi PB, Perales MA, Devlin SM, Olson A, Lubin M, Gonzales AM, Scaradavou A, Kernan NA, O'Reilly RJ, Giralt S, Jakubowski A, Koehne G, Papadopoulos EB, Ponce DM, Sauter C, Papanicolaou G, Barker JN. Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant. Leuk Lymphoma. 2015;56:1799-1805. [PMID: 25224458 DOI: 10.3109/10428194.2014.963079] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
206 Lurain NS, Chou S. Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev. 2010;23:689-712. [PMID: 20930070 DOI: 10.1128/cmr.00009-10] [Cited by in Crossref: 371] [Cited by in F6Publishing: 156] [Article Influence: 30.9] [Reference Citation Analysis]
207 Forlanini F, Dara J, Dvorak CC, Cowan MJ, Puck JM, Dorsey MJ. Unknown cytomegalovirus serostatus in primary immunodeficiency disorders: A new category of transplant recipients. Transpl Infect Dis 2021;23:e13504. [PMID: 33169931 DOI: 10.1111/tid.13504] [Reference Citation Analysis]
208 Dioverti MV, Razonable RR. Cytomegalovirus. Microbiol Spectr. 2016;4. [PMID: 27726793 DOI: 10.1128/microbiolspec.dmih2-0022-2015] [Cited by in Crossref: 43] [Cited by in F6Publishing: 22] [Article Influence: 8.6] [Reference Citation Analysis]
209 Heininger A, Haeberle H, Fischer I, Beck R, Riessen R, Rohde F, Meisner C, Jahn G, Koenigsrainer A, Unertl K, Hamprecht K. Cytomegalovirus reactivation and associated outcome of critically ill patients with severe sepsis. Crit Care 2011;15:R77. [PMID: 21362193 DOI: 10.1186/cc10069] [Cited by in Crossref: 87] [Cited by in F6Publishing: 73] [Article Influence: 7.9] [Reference Citation Analysis]
210 Emery V, Zuckerman M, Jackson G, Aitken C, Osman H, Pagliuca A, Potter M, Peggs K, Clark A; The British Committee for Standards in Haematology, the British Society of Blood and Marrow Transplantation and the UK Virology Network. Management of cytomegalovirus infection in haemopoietic stem cell transplantation. Br J Haematol 2013;162:25-39. [DOI: 10.1111/bjh.12363] [Cited by in Crossref: 72] [Cited by in F6Publishing: 61] [Article Influence: 8.0] [Reference Citation Analysis]
211 Stanley K, Ranganathan S, Mazariegos G, Bond G, Soltys K, Ganoza A, Jones K, Cieply K, Sindhi R. Donor mucosal immunocytes perpetuate refractory GVHD after intestinal transplantation without engrafting in recipient bone marrow: Case report and review of the literature. Pediatr Transplant 2019;23:e13350. [PMID: 30672115 DOI: 10.1111/petr.13350] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
212 Dhuruvasan K, Sivasubramanian G, Pellett PE. Roles of host and viral microRNAs in human cytomegalovirus biology. Virus Res 2011;157:180-92. [PMID: 20969901 DOI: 10.1016/j.virusres.2010.10.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
213 Shedlock DJ, Talbott KT, Wu SJ, Wilson CM, Muthumani K, Boyer JD, Sardesai NY, Awasthi S, Weiner DB. Vaccination with synthetic constructs expressing cytomegalovirus immunogens is highly T cell immunogenic in mice. Hum Vaccin Immunother 2012;8:1668-81. [PMID: 23151448 DOI: 10.4161/hv.22447] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
214 Micklethwaite KP, Savoldo B, Hanley PJ, Leen AM, Demmler-Harrison GJ, Cooper LJ, Liu H, Gee AP, Shpall EJ, Rooney CM, Heslop HE, Brenner MK, Bollard CM, Dotti G. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood 2010;115:2695-703. [PMID: 20110422 DOI: 10.1182/blood-2009-09-242263] [Cited by in Crossref: 82] [Cited by in F6Publishing: 78] [Article Influence: 6.8] [Reference Citation Analysis]
215 Ye B, Zhao H. Early abnormal liver enzyme levels may increase the prevalence of human cytomegalovirus antigenaemia after hematopoietic stem cell transplantation. J Int Med Res 2017;45:673-9. [PMID: 28415934 DOI: 10.1177/0300060516689013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
216 Kobayashi R, Hori D, Matsushima S, Sano H, Suzuki D, Kobayashi K. Lower gamma globulin level before conditioning is a risk factor for cytomegalovirus antigenemia after pediatric allogeneic stem cell transplantation. Pediatr Blood Cancer 2019;66:e27586. [PMID: 30556301 DOI: 10.1002/pbc.27586] [Reference Citation Analysis]
217 Komatsu TE, Pikis A, Naeger LK, Harrington PR. Resistance of human cytomegalovirus to ganciclovir/valganciclovir: A comprehensive review of putative resistance pathways. Antiviral Research 2014;101:12-25. [DOI: 10.1016/j.antiviral.2013.10.011] [Cited by in Crossref: 55] [Cited by in F6Publishing: 43] [Article Influence: 6.9] [Reference Citation Analysis]
218 Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, Hubacek P, Navarro D, Cordonnier C, Ward KN; 2017 European Conference on Infections in Leukaemia group. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 2019;19:e260-72. [PMID: 31153807 DOI: 10.1016/S1473-3099(19)30107-0] [Cited by in Crossref: 96] [Cited by in F6Publishing: 45] [Article Influence: 32.0] [Reference Citation Analysis]
219 Bruinsma M, Wils EJ, Löwenberg B, Cornelissen JJ, Braakman E. The impact of CD4+Foxp3+ Treg on immunity to murine cytomegalovirus after bone marrow transplantation depends on the peripheral or thymic source of T cell regeneration. Transpl Immunol 2010;24:9-16. [PMID: 20801217 DOI: 10.1016/j.trim.2010.08.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
220 Kachur E, Roshdy D, Hamadeh I, Dodd B, Shahid Z. Single-center experience with use of letermovir for treatment of CMV infection in stem cell transplant recipients. Transpl Infect Dis 2021;23:e13502. [PMID: 33171005 DOI: 10.1111/tid.13502] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
221 Inagaki J, Noguchi M, Kurauchi K, Tanioka S, Fukano R, Okamura J. Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Leukemia. Biol Blood Marrow Transplant 2016;22:300-6. [PMID: 26371373 DOI: 10.1016/j.bbmt.2015.09.006] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
222 Thompson PA, Rezvani K, Hosing CM, Oran B, Olson AL, Popat UR, Alousi AM, Shah ND, Parmar S, Bollard C, Hanley P, Kebriaei P, Cooper L, Kellner J, McNiece IK, Shpall EJ. Umbilical cord blood graft engineering: challenges and opportunities. Bone Marrow Transplant 2015;50 Suppl 2:S55-62. [PMID: 26039209 DOI: 10.1038/bmt.2015.97] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
223 Hakki M. Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy. Curr Hematol Malig Rep 2020;15:90-102. [PMID: 31981100 DOI: 10.1007/s11899-020-00557-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
224 Jung S, Michel M, Stamminger T, Michel D. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient. BMC Infect Dis 2019;19:388. [PMID: 31068147 DOI: 10.1186/s12879-019-4016-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 10.7] [Reference Citation Analysis]
225 Ito JI, Kriengkauykiat J, Dadwal SS, Arfons LM, Lazarus HM. Approaches to the early treatment of invasive fungal infection. Leuk Lymphoma 2010;51:1623-31. [PMID: 20629521 DOI: 10.3109/10428194.2010.496504] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
226 Houldcroft CJ, Bryant JM, Depledge DP, Margetts BK, Simmonds J, Nicolaou S, Tutill HJ, Williams R, Worth AJ, Marks SD, Veys P, Whittaker E, Breuer J. Detection of Low Frequency Multi-Drug Resistance and Novel Putative Maribavir Resistance in Immunocompromised Pediatric Patients with Cytomegalovirus. Front Microbiol 2016;7:1317. [PMID: 27667983 DOI: 10.3389/fmicb.2016.01317] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 8.0] [Reference Citation Analysis]
227 McLaughlin LP, Bollard CM, Keller M. Adoptive T Cell Immunotherapy for Patients with Primary Immunodeficiency Disorders. Curr Allergy Asthma Rep 2017;17:3. [PMID: 28116637 DOI: 10.1007/s11882-017-0669-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
228 Kim B, Choi YJ, Seo H, Shin EC, Choi S. Deterministic Migration-Based Separation of White Blood Cells. Small 2016;12:5159-68. [PMID: 27490148 DOI: 10.1002/smll.201601652] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
229 Locatelli F, Bertaina A, Bertaina V, Merli P. Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection. Expert Rev Hematol 2016;9:1093-105. [PMID: 27690683 DOI: 10.1080/17474086.2016.1242406] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
230 Zavras P, Su Y, Fang J, Stern A, Gupta N, Tang Y, Raval A, Giralt S, Perales MA, Jakubowski AA, Papanicolaou GA. Impact of Preemptive Therapy for Cytomegalovirus on Toxicities after Allogeneic Hematopoietic Cell Transplantation in Clinical Practice: A Retrospective Single-Center Cohort Study. Biol Blood Marrow Transplant 2020;26:1482-91. [PMID: 32315708 DOI: 10.1016/j.bbmt.2020.03.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
231 Muñoz-cobo B, Solano C, Costa E, Bravo D, Clari MÁ, Benet I, Remigia MJ, Montoro J, Navarro D. Dynamics of Cytomegalovirus (CMV) Plasma DNAemia in Initial and Recurrent Episodes of Active CMV Infection in the Allogeneic Stem Cell Transplantation Setting: Implications for Designing Preemptive Antiviral Therapy Strategies. Biology of Blood and Marrow Transplantation 2011;17:1602-11. [DOI: 10.1016/j.bbmt.2011.08.014] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
232 Talano JM, Pulsipher MA, Symons HJ, Militano O, Shereck EB, Giller RH, Hancock L, Morris E, Cairo MS. New frontiers in pediatric Allo-SCT. Bone Marrow Transplant 2014;49:1139-45. [PMID: 24820213 DOI: 10.1038/bmt.2014.89] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
233 Vehreschild MJ, Vehreschild JJ, Hübel K, Hentrich M, Schmidt-Hieber M, Christopeit M, Maschmeyer G, Schalk E, Cornely OA, Neumann S; German Society of Hematology and Oncology. Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Oncol 2013;24:1189-202. [PMID: 23401037 DOI: 10.1093/annonc/mdt001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
234 Ganly P, Cole S, Trengrove A, Butler A. Outcomes of allogeneic haemopoietic stem cell transplants at a small New Zealand centre: does size matter? Intern Med J 2014;44:683-9. [PMID: 24750295 DOI: 10.1111/imj.12456] [Reference Citation Analysis]
235 Peffault De Latour R, Chevallier P, Blaise D, Alami S, Lévy-Bachelot L, Allavoine T, Tadmouri A, Blomkvist J, Duhamel A, Srour M, Beauvais D, Yakoub-Agha I. Clinical and economic impact of treated CMV infection in adult CMV-seropositive patients after allogeneic hematopoietic cell transplantation. J Med Virol 2020. [PMID: 32297984 DOI: 10.1002/jmv.25895] [Reference Citation Analysis]
236 Ho SA, Slavin M, Roberts JA, Yong M. Optimization of Ganciclovir use in allogeneic hematopoietic cell transplant recipients - the role of therapeutic drug monitoring. Expert Rev Anti Infect Ther 2021;19:707-18. [PMID: 33201745 DOI: 10.1080/14787210.2021.1851193] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
237 Giulieri S, Manuel O. QuantiFERON®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity. Expert Rev Mol Diagn 2011;11:17-25. [PMID: 21171917 DOI: 10.1586/erm.10.109] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
238 Verghese PS, Schleiss MR. Letermovir Treatment of Human Cytomegalovirus Infection Antiinfective Agent. Drugs Future 2013;38:291-8. [PMID: 24163496 DOI: 10.1358/dof.2013.038.05.1946425] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
239 Solano C, Giménez E, Piñana JL, Vinuesa V, Poujois S, Zaragoza S, Calabuig M, Navarro D. Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood. Bone Marrow Transplant 2016;51:718-21. [DOI: 10.1038/bmt.2015.303] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
240 Yong MK, Gottlieb D, Lindsay J, Kok J, Rawlinson W, Slavin M, Ritchie D, Bajel A, Grigg A. New advances in the management of cytomegalovirus in allogeneic haemopoietic stem cell transplantation. Intern Med J 2020;50:277-84. [PMID: 31403736 DOI: 10.1111/imj.14462] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
241 Corrales I, Solano C, Amat P, Giménez E, de la Cámara R, Nieto J, López J, García-Noblejas A, Piñana JL, Navarro D. IL28B genetic variation and cytomegalovirus-specific T-cell immunity in allogeneic stem cell transplant recipients. J Med Virol 2017;89:685-95. [PMID: 27591738 DOI: 10.1002/jmv.24676] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
242 Nakamae H, Storer B, Sandmaier BM, Maloney DG, Davis C, Corey L, Storb R, Boeckh M. Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs. Haematologica 2011;96:1838-45. [PMID: 21880629 DOI: 10.3324/haematol.2011.044966] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
243 Xia L, Su R, An Z, Fu TM, Luo W. Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy. Hum Vaccin Immunother 2018;14:292-303. [PMID: 29053403 DOI: 10.1080/21645515.2017.1391433] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
244 Bravo AM, Arango J, Ramirez O, Portilla CA, López P, Calle JP, López-Medina E. Infectious complications after allogeneic hematopoietic stem cell transplantation in children in a bone marrow transplant unit in Colombia. Transpl Infect Dis 2021;23:e13498. [PMID: 33119920 DOI: 10.1111/tid.13498] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
245 Duarte RF, Lyon S. Novel approaches to CMV after HCT: report from the 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 22-25 April 2017. Future Sci OA 2018;4:FSO296. [PMID: 29796299 DOI: 10.4155/fsoa-2018-0013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
246 Camargo JF, Komanduri KV. Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther 2017;10:233-8. [PMID: 28641094 DOI: 10.1016/j.hemonc.2017.05.001] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 9.8] [Reference Citation Analysis]
247 Griffiths PD, Stanton A, McCarrell E, Smith C, Osman M, Harber M, Davenport A, Jones G, Wheeler DC, O’Beirne J. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial. Lancet. 2011;377:1256-1263. [PMID: 21481708 DOI: 10.1016/s0140-6736(11)60136-0] [Cited by in Crossref: 293] [Cited by in F6Publishing: 148] [Article Influence: 26.6] [Reference Citation Analysis]
248 Fonseca Brito L, Brune W, Stahl FR. Cytomegalovirus (CMV) Pneumonitis: Cell Tropism, Inflammation, and Immunity. Int J Mol Sci 2019;20:E3865. [PMID: 31398860 DOI: 10.3390/ijms20163865] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
249 Kaynar L, Metan G, Gökahmetoğlu S, Kurnaz F, Mumcuoğlu H, Öztürk A, Şıvgın S, Pala Ç, Yıldız O, Eser B, Ünal A, Çetin M. Can low-dose preemptive valganciclovir replace standard intravenous ganciclovir treatment in recipients of allogeneic stem cell transplantation? Journal of Chemotherapy 2013;25:286-91. [DOI: 10.1179/1973947813y.0000000082] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
250 Haynes RJ, Kline MC, Toman B, Scott C, Wallace P, Butler JM, Holden MJ. Standard reference material 2366 for measurement of human cytomegalovirus DNA. J Mol Diagn 2013;15:177-85. [PMID: 23321018 DOI: 10.1016/j.jmoldx.2012.09.007] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 5.3] [Reference Citation Analysis]
251 Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai SY, Rowley SD, Kebriaei P, Dey BR, Grilley BJ, Gee AP, Brenner MK, Rooney CM, Heslop HE. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013;121:5113-23. [PMID: 23610374 DOI: 10.1182/blood-2013-02-486324] [Cited by in Crossref: 345] [Cited by in F6Publishing: 306] [Article Influence: 38.3] [Reference Citation Analysis]
252 Quintela A, Escuret V, Roux S, Bonnafous P, Gilis L, Barraco F, Labussière-Wallet H, Duscastelle-Leprêtre S, Nicolini FE, Thomas X, Chidiac C, Ferry T, Frobert E, Morisset S, Poitevin-Later F, Monneret G, Michallet M, Ader F; Lyon HEMINF Study Group. HHV-6 infection after allogeneic hematopoietic stem cell transplantation: From chromosomal integration to viral co-infections and T-cell reconstitution patterns. J Infect 2016;72:214-22. [PMID: 26518057 DOI: 10.1016/j.jinf.2015.09.039] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
253 Sakamoto K, Nakasone H, Wada H, Yamasaki R, Ishihara Y, Kawamura K, Ashizawa M, Sato M, Terasako-Saito K, Machishima T, Kimura S, Kikuchi M, Kako S, Kanda J, Yamazaki R, Tanihara A, Nishida J, Kanda Y. Evaluation of the validity of preemptive therapy against cytomegalovirus disease based on antigenemia assay with a cutoff of 20 positive cells per two slides. PLoS One 2013;8:e73754. [PMID: 24040054 DOI: 10.1371/journal.pone.0073754] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
254 de Pagter PJ, Schuurman R, Keukens L, Schutten M, Cornelissen JJ, van Baarle D, Fries E, Sanders EA, Minnema MC, van der Holt BR, Meijer E, Boelens JJ. Human herpes virus 6 reactivation: important predictor for poor outcome after myeloablative, but not non-myeloablative allo-SCT. Bone Marrow Transplant 2013;48:1460-4. [PMID: 23771003 DOI: 10.1038/bmt.2013.78] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
255 Solano C, Giménez E, Piñana JL, Hernández-Boluda JC, Amat P, Vinuesa V, Navarro D. When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients? Bone Marrow Transplant 2017;52:1448-51. [PMID: 28581458 DOI: 10.1038/bmt.2017.109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
256 Sidoti F, Piralla A, Costa C, Scarasciulli ML, Calvario A, Conaldi PG, Paba P, Perno CF, Gaeta A, Antonelli G, Sodano G, Santangelo R, Sanguinetti M, Vatteroni ML, Barzon L, Palù G, Abbate I, Capobianchi MR, Piccirilli G, Lazzarotto T, Baldanti F, Cavallo R. Collaborative national multicenter for the identification of conversion factors from copies/mL to international units/mL for the normalization of HCMV DNA load. Diagnostic Microbiology and Infectious Disease 2019;95:152-8. [DOI: 10.1016/j.diagmicrobio.2019.05.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
257 Solano C, de la Cámara R, Vázquez L, López J, Giménez E, Navarro D. Cytomegalovirus Infection Management in Allogeneic Stem Cell Transplant Recipients: a National Survey in Spain. J Clin Microbiol 2015;53:2741-4. [PMID: 26063857 DOI: 10.1128/JCM.01057-15] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
258 Rastogi S, Ricci A, Jin Z, Bhatia M, George D, Garvin JH, Hall M, Satwani P. Clinical and Economic Impact of Cytomegalovirus Infection among Children Undergoing Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation 2019;25:1253-9. [DOI: 10.1016/j.bbmt.2018.11.028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
259 Odendahl M, Grigoleit GU, Bönig H, Neuenhahn M, Albrecht J, Anderl F, Germeroth L, Schmitz M, Bornhäuser M, Einsele H, Seifried E, Busch DH, Tonn T. Clinical-scale isolation of 'minimally manipulated' cytomegalovirus-specific donor lymphocytes for the treatment of refractory cytomegalovirus disease. Cytotherapy 2014;16:1245-56. [PMID: 25108651 DOI: 10.1016/j.jcyt.2014.05.023] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 5.6] [Reference Citation Analysis]
260 Bateman CM, Kesson A, Powys M, Wong M, Blyth E. Cytomegalovirus Infections in Children with Primary and Secondary Immune Deficiencies. Viruses 2021;13:2001. [PMID: 34696432 DOI: 10.3390/v13102001] [Reference Citation Analysis]
261 Karami S, Roshandel E, Ghaffari Nazari H, Hajifathali A, Tavakoli F, Parkhideh S. In-depth summary over cytomegalovirus infection in allogeneic hematopoietic stem cell transplantation recipients. Virusdisease 2021;32:422-34. [PMID: 34631973 DOI: 10.1007/s13337-021-00728-w] [Reference Citation Analysis]
262 El-haddad D, El Chaer F, Vanichanan J, Shah DP, Ariza-heredia EJ, Mulanovich VE, Gulbis AM, Shpall EJ, Chemaly RF. Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: A single-center experience. Antiviral Research 2016;134:58-62. [DOI: 10.1016/j.antiviral.2016.08.024] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
263 Arai T, Inoue Y, Tachibana K, Tsuyuguchi K, Nishiyama A, Sugimoto C, Sasaki Y, Kagawa T, Matsuda Y, Hayashi S. Cytomegalovirus infection during immunosuppressive therapy for diffuse parenchymal lung disease: CMV antigenaemia in DPLD. Respirology 2013;18:117-24. [DOI: 10.1111/j.1440-1843.2012.02263.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
264 Grossi PA, Baldanti F, Andreoni M, Perno CF. CMV infection management in transplant patients in Italy. J Clin Virol 2020;123:104211. [PMID: 31879243 DOI: 10.1016/j.jcv.2019.104211] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
265 Bollard CM, Heslop HE. T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood 2016;127:3331-40. [PMID: 27207801 DOI: 10.1182/blood-2016-01-628982] [Cited by in Crossref: 114] [Cited by in F6Publishing: 101] [Article Influence: 19.0] [Reference Citation Analysis]
266 Sell S, Dietz M, Schneider A, Holtappels R, Mach M, Winkler TH. Control of murine cytomegalovirus infection by γδ T cells. PLoS Pathog 2015;11:e1004481. [PMID: 25658831 DOI: 10.1371/journal.ppat.1004481] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
267 Kim SJ, Huang YT, Foldi J, Lee YJ, Maloy M, Giralt SA, Jakubowski AA, Papanicolaou GA. Cytomegalovirus resistance in CD34+ -selected hematopoietic cell transplant recipients. Transpl Infect Dis 2018;20:e12881. [PMID: 29570237 DOI: 10.1111/tid.12881] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
268 Wang E, Jan AS, Doan VP, Ferguson JB, Yeh JC. Leflunomide therapy for refractory cytomegalovirus infections in hematopoietic stem cell transplant recipients. J Oncol Pharm Pract 2019;25:1731-7. [PMID: 30170516 DOI: 10.1177/1078155218796188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
269 Choi S, Hwang J, Park K, Kim Y, Lee S, Yoo K, Kang E, Ahn J, Sung K, Koo H, Kim Y. The impact of drug-resistant cytomegalovirus in pediatric allogeneic hematopoietic cell transplant recipients: a prospective monitoring of UL97 and UL54 gene mutations. Transpl Infect Dis 2014;16:919-29. [DOI: 10.1111/tid.12311] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
270 Bay JO, Peffault de Latour R, Bruno B, Coiteux V, Guillaume T, Hicheri Y, Paillard C, Suarez F, Turlure P, Alain S, Bulabois CE, Socié G, Bauters F, Yakoub-Agha I; SFGM-TC. [Diagnosis and treatment of CMV and EBV Reactivation as well as Post-transplant Lymphoproliferative Disorders following Allogeneic Stem Cell Transplantation: An SFGM-TC report]. Pathol Biol (Paris) 2013;61:152-4. [PMID: 24011961 DOI: 10.1016/j.patbio.2013.07.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
271 Koldehoff M, Lindemann M, Ross SR, Elmaagacli AH. Cytomegalovirus induces HLA-class-II-restricted alloreactivity in an acute myeloid leukemia cell line. PLoS One 2018;13:e0191482. [PMID: 29377903 DOI: 10.1371/journal.pone.0191482] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
272 Hakki M, Ljungman P. Cytomegalovirus Infection After Stem Cell Transplantation. In: Ljungman P, Snydman D, Boeckh M, editors. Transplant Infections. Cham: Springer International Publishing; 2016. pp. 417-40. [DOI: 10.1007/978-3-319-28797-3_24] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
273 Tong J, Sun Z, Liu H, Geng L, Zheng C, Tang B, Song K, Yao W, Liu X. Risk factors of CMV infection in patients after umbilical cord blood transplantation: a multicenter study in China. Chin J Cancer Res. 2013;25:695-703. [PMID: 24385697 DOI: 10.3978/j.issn.1000-9604.2013.11.08] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
274 Chen K, Arbona-Haddad E, Cheng MP, McDonnell AM, Gooptu M, Orejas JL, Timblin K, Silverman E, Al-Hamed R, Soiffer RJ, Hammond SP, Marty FM. Cytomegalovirus events in high-risk allogeneic hematopoietic-cell transplantation patients who received letermovir prophylaxis. Transpl Infect Dis 2021;:e13619. [PMID: 33866648 DOI: 10.1111/tid.13619] [Reference Citation Analysis]
275 Herr W, Plachter B. Cytomegalovirus and varicella–zoster virus vaccines in hematopoietic stem cell transplantation. Expert Review of Vaccines 2014;8:999-1021. [DOI: 10.1586/erv.09.58] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
276 Mori T, Kato J. Cytomegalovirus infection/disease after hematopoietic stem cell transplantation. Int J Hematol 2010;91:588-95. [PMID: 20414753 DOI: 10.1007/s12185-010-0569-x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 4.3] [Reference Citation Analysis]
277 Oltolini C, Greco R, Galli L, Clerici D, Lorentino F, Xue E, Lupo Stanghellini MT, Giglio F, Uhr L, Ripa M, Scarpellini P, Bernardi M, Corti C, Peccatori J, Castagna A, Ciceri F. Infections after Allogenic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching. Biol Blood Marrow Transplant 2020;26:1179-88. [PMID: 32004700 DOI: 10.1016/j.bbmt.2020.01.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
278 Boeckh M. Complications, Diagnosis, Management, and Prevention of CMV Infections: Current and Future. Hematology 2011;2011:305-9. [DOI: 10.1182/asheducation-2011.1.305] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 5.3] [Reference Citation Analysis]
279 Duraisamy SK, Mammen S, Lakshminarayan SKR, Verghese S, Moorthy M, George B, Kannangai R, Varghese S, Srivastava A, Abraham AM. Performance of an in-house real-time PCR assay for detecting Cytomegalovirus infection among transplant patients from a tertiary care centre. Indian J Med Microbiol 2018;36:241-6. [PMID: 30084418 DOI: 10.4103/ijmm.IJMM_18_126] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
280 Kato T, Nishida T, Ito Y, Murase M, Murata M, Naoe T. Correlations of programmed death 1 expression and serum IL-6 level with exhaustion of cytomegalovirus-specific T cells after allogeneic hematopoietic stem cell transplantation. Cellular Immunology 2014;288:53-9. [DOI: 10.1016/j.cellimm.2014.02.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
281 Rasheed W, Ghavamzadeh A, Hamladji R, Othman TB, Alseraihy A, Abdel-rahman F, Elhaddad A, Alabdulaaly A, Dennison D, Ibrahim A, Bazarbachi A, Bekadja M, Mohamed SY, Adil SN, Ahmed P, Benchekroun S, Ramzi M, Jarrar M, Alimoghaddam K, Hussain F, Hamidieh A, Aljurf M. Hematopoietic stem cell transplantation practice variation among centers in the Eastern Mediterranean Region (EMRO): Eastern Mediterranean Bone Marrow Transplantation (EMBMT) group survey. Hematology/Oncology and Stem Cell Therapy 2013;6:14-9. [DOI: 10.1016/j.hemonc.2013.04.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
282 Blyth E, Clancy L, Simms R, Ma CKK, Burgess J, Deo S, Byth K, Dubosq M, Shaw PJ, Micklethwaite KP, Gottlieb DJ. Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation. Blood 2013;121:3745-58. [DOI: 10.1182/blood-2012-08-448977] [Cited by in Crossref: 155] [Cited by in F6Publishing: 144] [Article Influence: 17.2] [Reference Citation Analysis]
283 Kanvinde S, Bhargava P, Patwardhan S. Cytomegalovirus infection as a cause of cytopenia after chemotherapy for hematological malignancies. Indian Pediatr 2013;50:197-201. [DOI: 10.1007/s13312-013-0066-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
284 Alsuliman T, Kitel C, Dulery R, Guillaume T, Larosa F, Cornillon J, Labussière-Wallet H, Médiavilla C, Belaiche S, Delage J, Alain S, Yakoub-Agha I. Cytotect®CP as salvage therapy in patients with CMV infection following allogeneic hematopoietic cell transplantation: a multicenter retrospective study. Bone Marrow Transplant 2018;53:1328-35. [PMID: 29654288 DOI: 10.1038/s41409-018-0166-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
285 Maffini E, Busca A, Costa C, Giaccone L, Cerrano M, Curtoni A, Cavallo R, Bruno B. An update on the treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol 2019;12:937-45. [PMID: 31423858 DOI: 10.1080/17474086.2019.1657399] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
286 Navarro D, Amat P, de la Cámara R, López J, Vázquez L, Serrano D, Nieto J, Rovira M, Piñana JL, Giménez E, Solano C. Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients. Open Forum Infect Dis 2016;3:ofw107. [PMID: 27419179 DOI: 10.1093/ofid/ofw107] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
287 Akpek G, Mikulski M, Kleinberg M, Badros A, Yanovich S, Rapoport AP. Cellular therapy with sequential unmanipulated donor lymphocyte infusions in drug-resistant cytomegalovirus (CMV) encephalitis. Blood 2011;117:5772-4. [PMID: 21617009 DOI: 10.1182/blood-2011-02-334060] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
288 Manjappa S, Bhamidipati PK, Stokerl-Goldstein KE, DiPersio JF, Uy GL, Westervelt P, Liu J, Schroeder MA, Vij R, Abboud CN, Fehniger TA, Cashen AF, Pusic I, Jacoby M, Meera SJ, Romee R. Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen. Biol Blood Marrow Transplant 2014;20:46-52. [PMID: 24120526 DOI: 10.1016/j.bbmt.2013.10.003] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 7.0] [Reference Citation Analysis]
289 Rustia E, Violago L, Jin Z, Foca MD, Kahn JM, Arnold S, Sosna J, Bhatia M, Kung AL, George D, Garvin JH, Satwani P. Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2016;22:1646-53. [PMID: 27252110 DOI: 10.1016/j.bbmt.2016.05.014] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
290 Jang JE, Hyun SY, Kim YD, Yoon SH, Hwang DY, Kim SJ, Kim Y, Kim JS, Cheong JW, Min YH. Risk factors for progression from cytomegalovirus viremia to cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012;18:881-6. [PMID: 22062802 DOI: 10.1016/j.bbmt.2011.10.037] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
291 Kharfan-dabaja MA, Boeckh M, Wilck MB, Langston AA, Chu AH, Wloch MK, Guterwill DF, Smith LR, Rolland AP, Kenney RT. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Infectious Diseases 2012;12:290-9. [DOI: 10.1016/s1473-3099(11)70344-9] [Cited by in Crossref: 188] [Cited by in F6Publishing: 86] [Article Influence: 18.8] [Reference Citation Analysis]
292 Abate D, Cesaro S, Cofano S, Fiscon M, Saldan A, Varotto S, Mengoli C, Pillon M, Calore E, Biasolo MA, Cusinato R, Barzon L, Messina C, Carli M, Palù G. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients. Transplantation 2012;93:536-42. [PMID: 22314338 DOI: 10.1097/TP.0b013e31824215db] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
293 Jinnouchi F, Mori Y, Yoshimoto G, Yamauchi T, Nunomura T, Yurino A, Hayashi M, Yuda J, Shima T, Odawara J, Takashima S, Kamezaki K, Kato K, Miyamoto T, Akashi K, Takenaka K. Incidence of refractory cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Int J Hematol 2021. [PMID: 34652633 DOI: 10.1007/s12185-021-03218-3] [Reference Citation Analysis]
294 Ogawa-Goto K, Ueno T, Oshima K, Yamamoto H, Sasaki J, Fujita K, Sata T, Taniguchi S, Kanda Y, Katano H. Detection of active human cytomegalovirus by the promyelocytic leukemia body assay in cultures of PBMCs from patients undergoing hematopoietic stem cell transplantation. J Med Virol 2012;84:479-86. [PMID: 22246835 DOI: 10.1002/jmv.23220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
295 Franck B, Woillard JB, Théorêt Y, Bittencourt H, Demers E, Briand A, Marquet P, Lapeyraque AL, Ovetchkine P, Autmizguine J. Population pharmacokinetics of ganciclovir and valganciclovir in paediatric solid organ and stem cell transplant recipients. Br J Clin Pharmacol 2021;87:3105-14. [PMID: 33373493 DOI: 10.1111/bcp.14719] [Reference Citation Analysis]
296 Maples KT, Maloy M, Devlin S, Lin A, DeRespiris L, Griffin M, Lau C, Proli AJ, Papanicolaou GA, Seo SK, Barker JN, Perales MA, Giralt SA, Bhatt V. Lack of a significant pharmacokinetic interaction between letermovir and calcineurin inhibitors in allogeneic HCT recipients. Bone Marrow Transplant 2020;55:1687-9. [PMID: 31937928 DOI: 10.1038/s41409-020-0785-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
297 Pereira MR, Pouch SM, Scully B. Infections in Allogeneic Stem Cell Transplantation. In: Safdar A, editor. Principles and Practice of Transplant Infectious Diseases. New York: Springer; 2019. pp. 209-26. [DOI: 10.1007/978-1-4939-9034-4_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
298 Yong MK, Slavin MA, Kontoyiannis DP. Invasive fungal disease and cytomegalovirus infection: is there an association? Curr Opin Infect Dis 2018;31:481-9. [PMID: 30299361 DOI: 10.1097/QCO.0000000000000502] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 6.3] [Reference Citation Analysis]
299 Zallio F, Primon V, Tamiazzo S, Pini M, Baraldi A, Corsetti MT, Gotta F, Bertassello C, Salvi F, Rocchetti A. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation. Clin Transplant. 2013;27:E491-E497. [PMID: 23781897 DOI: 10.1111/ctr.12172] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
300 Maertens J, Logan AC, Jang J, Long G, Tang JL, Hwang WYK, Koh LP, Chemaly R, Gerbitz A, Winkler J, Yeh SP, Hiemenz J, Christoph S, Lee DG, Wang PN, Holler E, Mielke S, Akard L, Yeo A, Ramachandra S, Smith K, Pertel P, Segal F. Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation. Antimicrob Agents Chemother 2020;64:e02467-19. [PMID: 32015031 DOI: 10.1128/AAC.02467-19] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
301 Keller MD, Darko S, Lang H, Ransier A, Lazarski CA, Wang Y, Hanley PJ, Davila BJ, Heimall JR, Ambinder RF, Barrett AJ, Rooney CM, Heslop HE, Douek DC, Bollard CM. T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy. Br J Haematol 2019;187:206-18. [PMID: 31219185 DOI: 10.1111/bjh.16053] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
302 Hammerstrom AE, Lombardi LR, Pingali SR, Rondon G, Chen J, Milton DR, Chemaly RF, Champlin RE, Gulbis A, Ciurea SO. Prevention of Cytomegalovirus Reactivation in Haploidentical Stem Cell Transplantation. Biol Blood Marrow Transplant 2018;24:353-8. [PMID: 28986189 DOI: 10.1016/j.bbmt.2017.09.018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
303 Breda G, Almeida B, Carstensen S, Bonfim CM, Nogueira MB, Vidal LR, Almeida SM, Raboni SM. Human cytomegalovirus detection by real-time PCR and pp65-antigen test in hematopoietic stem cell transplant recipients: a challenge in low and middle-income countries. Pathog Glob Health 2013;107:312-9. [PMID: 24188241 DOI: 10.1179/2047773213Y.0000000114] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
304 Lilleri D, Gerna G, Zelini P, Chiesa A, Rognoni V, Mastronuzzi A, Giorgiani G, Zecca M, Locatelli F. Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation. PLoS One 2012;7:e41648. [PMID: 22848556 DOI: 10.1371/journal.pone.0041648] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
305 Daniels K, Clemmons A. Letermovir for Cytomegalovirus Prevention in Patients Undergoing Hematopoietic Cell Transplantation. J Adv Pract Oncol 2019;10:730-5. [PMID: 33391856 DOI: 10.6004/jadpro.2019.10.7.8] [Reference Citation Analysis]
306 Villa NY, McFadden G. Virotherapy as Potential Adjunct Therapy for Graft-Vs-Host Disease. Curr Pathobiol Rep 2018;6:247-63. [PMID: 30595970 DOI: 10.1007/s40139-018-0186-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
307 Boonyaratanakornkit J, Vivek M, Xie H, Pergam SA, Cheng GS, Mielcarek M, Hill JA, Jerome KR, Limaye AP, Leisenring W, Boeckh MJ, Waghmare A. Predictive Value of Respiratory Viral Detection in the Upper Respiratory Tract for Infection of the Lower Respiratory Tract With Hematopoietic Stem Cell Transplantation. J Infect Dis 2020;221:379-88. [PMID: 31541573 DOI: 10.1093/infdis/jiz470] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
308 Suárez NM, Blyth E, Li K, Ganzenmueller T, Camiolo S, Avdic S, Withers B, Linnenweber-Held S, Gwinner W, Dhingra A, Heim A, Schulz TF, Gunson R, Gottlieb D, Slobedman B, Davison AJ. Whole-Genome Approach to Assessing Human Cytomegalovirus Dynamics in Transplant Patients Undergoing Antiviral Therapy. Front Cell Infect Microbiol 2020;10:267. [PMID: 32612959 DOI: 10.3389/fcimb.2020.00267] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
309 El Haddad L, Ariza-Heredia E, Shah DP, Jiang Y, Blanchard T, Ghantoji SS, El Chaer F, El-Haddad D, Prayag A, Nesher L, Rezvani K, Shpall E, Chemaly RF. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients. J Infect Dis 2019;219:898-907. [PMID: 30295846 DOI: 10.1093/infdis/jiy592] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 13.5] [Reference Citation Analysis]
310 Ganzenmueller T, Heim A. Adenoviral load diagnostics by quantitative polymerase chain reaction: techniques and application. Rev Med Virol 2012;22:194-208. [PMID: 22162042 DOI: 10.1002/rmv.724] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
311 Yamazaki R, Tanaka Y, Nakasone H, Sato M, Terasako-saito K, Sakamoto K, Akahoshi Y, Nakano H, Ugai T, Yamasaki R, Wada H, Ishihara Y, Kawamura K, Ashizawa M, Kimura S, Kikuchi M, Kako S, Kanda J, Tanihara A, Nishida J, Kanda Y. Allotype analysis to determine the origin of cytomegalovirus immunoglobulin-G after allogeneic stem cell transplantation. Transpl Infect Dis 2014;16:904-13. [DOI: 10.1111/tid.12304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
312 Mengarelli A, Annibali O, Pimpinelli F, Riva E, Gumenyuk S, Renzi D, Cerchiara E, Piccioni L, Palombi F, Pisani F, Romano A, Spadea A, Papa E, Cordone I, Canfora M, Arcese W, Ensoli F, Marchesi F. Prospective surveillance vs clinically driven approach for CMV reactivation after autologous stem cell transplant. J Infect 2016;72:265-8. [PMID: 26687516 DOI: 10.1016/j.jinf.2015.11.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
313 Baldo F, Suárez NM, Davison AJ, Zanon D, Barbi E, Maximova N. Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report. Antiviral Res 2021;188:105024. [PMID: 33577809 DOI: 10.1016/j.antiviral.2021.105024] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
314 Proff J, Walterskirchen C, Brey C, Geyeregger R, Full F, Ensser A, Lehner M, Holter W. Cytomegalovirus-Infected Cells Resist T Cell Mediated Killing in an HLA-Recognition Independent Manner. Front Microbiol 2016;7:844. [PMID: 27375569 DOI: 10.3389/fmicb.2016.00844] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
315 Tsai HP, Yeh CS, Lin IT, Ko WC, Wang JR. Increasing Cytomegalovirus Detection Rate from Respiratory Tract Specimens by a New Laboratory-Developed Automated Molecular Diagnostic Test. Microorganisms 2020;8:E1063. [PMID: 32708818 DOI: 10.3390/microorganisms8071063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
316 Zerr DM, Boeckh M, Delaney C, Martin PJ, Xie H, Adler AL, Huang ML, Corey L, Leisenring WM. HHV-6 reactivation and associated sequelae after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012;18:1700-8. [PMID: 22641196 DOI: 10.1016/j.bbmt.2012.05.012] [Cited by in Crossref: 81] [Cited by in F6Publishing: 72] [Article Influence: 8.1] [Reference Citation Analysis]
317 Khansarinejad B, Soleimanjahi H, Mirab Samiee S, Hamidieh AA, Paryan M, Sanahmadi Y, Karami M, Mondanizadeh M. Monitoring human cytomegalovirus infection in pediatric hematopoietic stem cell transplant recipients: using an affordable in-house qPCR assay for management of HCMV infection under limited resources. Transpl Int 2015;28:594-603. [DOI: 10.1111/tri.12545] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
318 Pitombeira BS, Paz A, Pezzi A, Amorin B, Valim V, Laureano A, Wieck A, Rigoni L, Ottoni E, Fisher G, Daudt L, Silla L. Validation of the EBMT Risk Score for South Brazilian Patients Submitted to Allogeneic Hematopoietic Stem Cell Transplantation. Bone Marrow Res 2013;2013:565824. [PMID: 24416593 DOI: 10.1155/2013/565824] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
319 Giménez E, Muñoz-Cobo B, Solano C, Amat P, Navarro D. Early kinetics of plasma cytomegalovirus DNA load in allogeneic stem cell transplant recipients in the era of highly sensitive real-time PCR assays: does it have any clinical value? J Clin Microbiol 2014;52:654-6. [PMID: 24478505 DOI: 10.1128/JCM.02571-13] [Cited by in Crossref: 24] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
320 Solano C, Muñoz-Cobo B, Giménez E, Remigia MJ, Amat P, Clari MA, Bravo D, Benet I, Montoro J, Navarro D. Pre-emptive antiviral therapy for active CMV infection in adult allo-SCT patients guided by plasma CMV DNAemia quantitation using a real-time PCR assay: clinical experience at a single center. Bone Marrow Transplant 2013;48:1010-2. [PMID: 23334275 DOI: 10.1038/bmt.2012.286] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
321 Suárez-Lledó M, Martínez-Cibrián N, Gutiérrez-García G, Dimova-Svetoslavova V, Marcos MA, Martín-Antonio B, Martínez-Trillos A, Villamor N, Rosiñol L, Martínez C, Fernández-Avilés F, García-Vidal C, Urbano-Ispizua Á, Rovira M. Deleterious Effect of Steroids on Cytomegalovirus Infection Rate after Allogeneic Stem Cell Transplantation Depends on Pretransplant Cytomegalovirus Serostatus of Donors and Recipients. Biol Blood Marrow Transplant 2018;24:2088-93. [PMID: 29753162 DOI: 10.1016/j.bbmt.2018.05.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
322 Ueda M, Berger M, Gale RP, Lazarus HM. Immunoglobulin therapy in hematologic neoplasms and after hematopoietic cell transplantation. Blood Reviews 2018;32:106-15. [DOI: 10.1016/j.blre.2017.09.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
323 Rowe RG, Guo D, Lee M, Margossian S, London WB, Lehmann L. Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection at a Single Center. Biol Blood Marrow Transplant 2016;22:1275-83. [PMID: 27090959 DOI: 10.1016/j.bbmt.2016.04.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
324 Vejrazkova E, Pliskova L, Hubacek P, Kostal M, Zavrelova A, Radocha J, Kutova R, Stepanova V, Zak P. Clinical and genotypic CMV drug resistance in HSCT recipients: a single center epidemiological and clinical data. Bone Marrow Transplant 2019;54:146-9. [PMID: 29950664 DOI: 10.1038/s41409-018-0257-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
325 Chevillotte M, Ersing I, Mertens T, von Einem J. Differentiation between polymorphisms and resistance-associated mutations in human cytomegalovirus DNA polymerase. Antimicrob Agents Chemother 2010;54:5004-11. [PMID: 20876378 DOI: 10.1128/AAC.00259-10] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
326 Einsele H, Ljungman P, Boeckh M. How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation. Blood 2020;135:1619-29. [PMID: 32202631 DOI: 10.1182/blood.2019000956] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
327 Menger L, Gouble A, Marzolini MA, Pachnio A, Bergerhoff K, Henry JY, Smith J, Pule M, Moss P, Riddell SR, Quezada SA, Peggs KS. TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells. Blood 2015;126:2781-9. [PMID: 26508783 DOI: 10.1182/blood-2015-08-664755] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
328 Ueno R, Nishimura S, Fujimoto G, Piao Y, Takenaka K. The clinical and economic burden of cytomegalovirus management post allogeneic hematopoietic stem cell transplantation in Japan - a retrospective database study. Curr Med Res Opin 2019;35:2089-96. [PMID: 31353971 DOI: 10.1080/03007995.2019.1649379] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
329 Noguchi T, Nishikawa T, Ishihara S. Rectocolic and colocolic fistulas accompanied by cytomegalovirus infection: Two case reports. Asian J Surg 2020;43:783-4. [PMID: 32199669 DOI: 10.1016/j.asjsur.2020.03.004] [Reference Citation Analysis]
330 Resende CB, Rezende BM, Bernardes PT, Teixeira GM, Teixeira MM, Pinho V, Bittencourt H. Alemtuzumab as graft-versus-host disease (GVHD) prophylaxis strategy in a developing country: lower rate of acute GVHD, increased risk of cytomegalovirus reactivation. Braz J Med Biol Res 2017;50:e5566. [PMID: 28198910 DOI: 10.1590/1414-431X20165566] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
331 Wolf DG, Shimoni A, Resnick IB, Stamminger T, Neumann AU, Chou S, Efferth T, Caplan O, Rose J, Nagler A, Marschall M. Human cytomegalovirus kinetics following institution of artesunate after hematopoietic stem cell transplantation. Antiviral Res 2011;90:183-6. [PMID: 21443904 DOI: 10.1016/j.antiviral.2011.03.184] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
332 Kanda Y, Yamashita T, Mori T, Ito T, Tajika K, Mori S, Sakura T, Hara M, Mitani K, Kurokawa M. A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT. Bone Marrow Transplant. 2010;45:1325-1332. [PMID: 19966850 DOI: 10.1038/bmt.2009.337] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
333 Pollack M, Heugel J, Xie H, Leisenring W, Storek J, Young JA, Kukreja M, Gress R, Tomblyn M, Boeckh M. An international comparison of current strategies to prevent herpesvirus and fungal infections in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2011;17:664-73. [PMID: 20699126 DOI: 10.1016/j.bbmt.2010.07.026] [Cited by in Crossref: 56] [Cited by in F6Publishing: 54] [Article Influence: 4.7] [Reference Citation Analysis]
334 Ma CKK, Clancy L, Simms R, Burgess J, Deo S, Blyth E, Micklethwaite KP, Gottlieb DJ. Adjuvant Peptide Pulsed Dendritic Cell Vaccination in Addition to T Cell Adoptive Immunotherapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Biol Blood Marrow Transplant 2018;24:71-7. [PMID: 28864137 DOI: 10.1016/j.bbmt.2017.08.028] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
335 Carapito R, Aouadi I, Pichot A, Spinnhirny P, Morlon A, Kotova I, Macquin C, Rolli V, Cesbron A, Gagne K, Oudshoorn M, van der Holt B, Labalette M, Spierings E, Picard C, Loiseau P, Tamouza R, Toubert A, Parissiadis A, Dubois V, Paillard C, Maumy-Bertrand M, Bertrand F, von dem Borne PA, Kuball JHE, Michallet M, Lioure B, Peffault de Latour R, Blaise D, Cornelissen JJ, Yakoub-Agha I, Claas F, Moreau P, Charron D, Mohty M, Morishima Y, Socié G, Bahram S. Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status. Bone Marrow Transplant 2020;55:1367-78. [PMID: 32286503 DOI: 10.1038/s41409-020-0886-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
336 Sauter C, Abboud M, Jia X, Heller G, Gonzales AM, Lubin M, Hawke R, Perales MA, van den Brink MR, Giralt S, Papanicolaou G, Scaradavou A, Small TN, Barker JN. Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. Biol Blood Marrow Transplant 2011;17:1460-71. [PMID: 21310254 DOI: 10.1016/j.bbmt.2011.02.001] [Cited by in Crossref: 79] [Cited by in F6Publishing: 74] [Article Influence: 7.2] [Reference Citation Analysis]
337 Terasako-saito K, Nakasone H, Tanaka Y, Yamazaki R, Sato M, Sakamoto K, Ishihara Y, Kawamura K, Akahoshi Y, Hayakawa J, Wada H, Harada N, Nakano H, Kameda K, Ugai T, Yamasaki R, Ashizawa M, Kimura S, Kikuchi M, Tanihara A, Kanda J, Kako S, Nishida J, Kanda Y. Persistence of recipient-derived as well as donor-derived clones of cytomegalovirus pp65-specific cytotoxic T cells long after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2014;16:930-40. [DOI: 10.1111/tid.12318] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
338 Schleiss MR, Patterson JC. Viral Infections of the Fetus and Newborn and Human Immunodeficiency Virus Infection during Pregnancy. Avery's Diseases of the Newborn. Elsevier; 2012. pp. 468-512. [DOI: 10.1016/b978-1-4377-0134-0.10037-x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
339 Pass RF. Human Herpesviruses: Cytomegalovirus. In: Kaslow RA, Stanberry LR, Le Duc JW, editors. Viral Infections of Humans. Boston: Springer US; 2014. pp. 805-28. [DOI: 10.1007/978-1-4899-7448-8_35] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
340 Wikstrom ME, Fleming P, Kuns RD, Schuster IS, Voigt V, Miller G, Clouston AD, Tey SK, Andoniou CE, Hill GR, Degli-Esposti MA. Acute GVHD results in a severe DC defect that prevents T-cell priming and leads to fulminant cytomegalovirus disease in mice. Blood 2015;126:1503-14. [PMID: 26130706 DOI: 10.1182/blood-2015-01-622837] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
341 Tsai HP, Tsai YY, Lin IT, Kuo PH, Chen TY, Chang KC, Wang JR. Comparison of Two Commercial Automated Nucleic Acid Extraction and Integrated Quantitation Real-Time PCR Platforms for the Detection of Cytomegalovirus in Plasma. PLoS One 2016;11:e0160493. [PMID: 27494707 DOI: 10.1371/journal.pone.0160493] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]